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ABSTRACT 
Amyotrophic lateral sclerosis (ALS) is a progressive adult neuro-
degenerative disease that causes death of both upper and lower motor neurons. 
Approximately 90 percent of ALS cases are sporadic (SALS), and 10 percent are 
inherited (FALS). Mutations in the PFN1 gene have been identified as causative 
for one percent of FALS. PFN1 is a small actin-binding protein that promotes 
actin polymerization, but how ALS-linked PFN1 mutations affect its cognate 
functions or acquire gain-of-function toxicity remains largely unknown.  
To elucidate the contribution of ALS-linked PFN1 mutations to 
neurodegeneration, we have characterized these mutants in both mammalian 
cultured cells and Drosophila models. In mammalian neuronal cells, we 
demonstrate that ALS-linked PFN1 mutants form ubiquitinated aggregates and 
alter neuronal morphology. We also show that ALS-linked PFN1 mutants have 
partial loss-of-function effects on actin polymerization in growth cones of mouse 
primary motor neurons and larval neuromuscular junctions (NMJ) in Drosophila.  
In Drosophila, we also observe that PFN1 level influences integrity of adult motor 
neurons, as demonstrated by locomotion, lifespan, and leg NMJ morphology.  
In sum, the work presented in this dissertation has shed light on PFN1-
linked ALS pathogenesis by demonstrating a loss-of-function mechanism. We 
have also developed a Drosophila PFN1 model that will serve as a valuable tool 
to further uncover PFN1-associated cellular pathways that mediate motor neuron 
functions. 
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CHAPTER I: INTRODUCTION 
1.1 What is Amyotrophic lateral sclerosis? 
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, 
is a debilitating neurodegenerative disease that selectively causes motor neuron 
death in both brain and spinal cord and leads to weakness of limb and bulbar 
muscles (reviewed in Wijesejera and Leign, 2009). The paralysis often starts 
focally and spreads throughout different regions, resulting in impaired critical 
functions such as swallowing, breathing, and speaking. The average age of 
onset is around 50 years, and juvenile ALS is uncommon. Patients usually die 
within 3 to 5 years after initial symptoms, although the clinical course and 
disease severity can vary, with some patients surviving for decades.   
Compared with other common neurodegenerative diseases, ALS is often 
considered an “orphan disease”. About 2 per 100,000 new cases are diagnosed 
each year, and its prevalence is about 5 per 100,000 total cases each year, 
making it the most common neuromuscular disease worldwide (reviewed in 
Peters et at, 2014). Currently there is no effective therapy for this disease, and 
most treatments involve symptom relief and supportive care. The only FDA-
approved drug, riluzole, unsatisfactorily prolongs survival by only 3 to 5 months 
(Bensimon, 1994; Lacomblez et al, 1996; Ludolph and Jesse, 2009). Therefore, 
the progressive character of ALS and lack of effective treatment require the 
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awareness of the public, and make it an important disease for scientists to 
investigate.  
Histo-pathologically, protein aggregates serve as a hallmark in post-
mortem brain tissues of ALS patients (Kanning et al 2010). These aggregates, 
which localize mostly in the cytoplasm of affected motor neurons, are 
ubiquitinated and formed by misfolded proteins. In many cases, they contain 
phosphorylated TAR DNA binding protein 43 (TDP-43) (Neumann et al, 2006). 
Interestingly, mutations in TDP-43 have also been identified as causative for ALS 
(Sreedharan et al, 2008). Apart from aggregates, loss of motor neurons in 
affected regions can also be detected, which is usually accompanied by gliosis 
(Wijesejera and Leign, 2009).  
Peripherally, neuromuscular junction denervation can also be found in 
biopsies of muscles from ALS patients (Fischer et al, 2004; Bruneteau et al, 
2015). Correspondingly, electrophysiological changes in electromyographic 
measurements are early signs in the course of the disease, indicative of the 
development of early distal axonopathy (Dengler et al, 1990; Frey et al, 2000; de 
Carvalho et al, 2008). In fact, a “dying-back” mechanism that views ALS as an 
axonopathy has been suggested in recent years (Fischer et al, 2004, reviewed in 
Moloney et al, 2014). For instance, in ALS mouse models, it has been shown that 
axonal retraction occurs before loss of neuronal cell bodies in the spinal cord, 
suggesting degenerating programs may start distally in synaptic regions and 
progress toward cell bodies, eventually leading to cell death (Fischer et al, 2004). 
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Furthermore, in ALS mouse model, blockage of cell apoptosis pathway prevents 
motor neuron death but not neuromuscular denervation, providing another line of 
evidence that neuromuscular denervation results from local degenerating 
molecular programs, rather than being a secondary effect of dying cell bodies 
(Gould et al, 2006). On the other hand, considering most ALS-associated mutant 
proteins have high propensity to aggregate and may impair neurons in multiple 
aspects, it is also likely that neuromuscular denervation is a general sign of 
neuronal dysfunctions (both in cell bodies and in axons). In all, while it is still not 
fully understood whether neuromuscular denervation is a primary cause of ALS 
or secondary to other pathogenic mechanisms,  these studies highlight the 
importance of NMJ integrity in ALS pathogenesis. 
 
1.2 What genetics factors cause ALS? 
Approximately 90% of ALS cases are sporadic (SALS), and 10% are 
inherited (familial ALS, FALS) (reviewed in Renton et al, 2014). FALS is mostly 
autosomal dominant and caused by mutations in heterogeneous genes. About 20 
years ago, by using linkage analysis, SOD1 was identified as the first gene that 
harbored missense mutations causing FALS (Rosen et al, 1993). SOD1 encodes 
superoxide dismutase 1, a protein involved in reducing reactive oxygen species, 
and up to date over a hundred mutations in SOD1 have been reported 
(Andersen, 2006). Since the discovery of SOD1 mutations, more genes that are 
involved in different cellular pathways have also been identified that contain 
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FALS-linked mutations (reviewed in Renton et al, 2014), e.g. TARDBP 
(Sreedharan et al, 2008), FUS (Kwiatkowski et al, 2009; Vance at al, 2009), VCP 
(Johnson et al, 2010), and UBQLN2 (Deng et al, 2011). Most of these mutations 
reside within coding regions that cause missense or nonsense alterations of 
amino acid sequences. However, several groups identified a hexanucleotide 
GGGGCC repeat expansion in the first intron of C9ORF72 (DeJesus-Hernandez 
et al, 2011; Renton, 2011; Glijselinck et al, 2012), which were estimated to 
account for about 40% of FALS cases. This finding thus stresses the relevance 
of alterations in noncoding genome to ALS genetics. Nonetheless, despite these 
progresses in gene discovery, it is still unknown what genetic factors contribute 
to approximately one third of FALS patients (Table I-1). Notably, de novo 
mutations in genes involved in FALS, such as SOD1, FUS, and C9ORF72, are 
also reported in SALS patients (reviewed in Renton, 2014). This highlights the 
importance of identification of novel gene mutations in FALS, which will help to 
shed light on common cellular pathways that underlie pathogenesis of both 
sporadic and familial ALS.  
 
1.3 ALS and frontotemporal lobar dementia 
Frontotemporal lobar dementia (FTLD) is the second most common type 
of dementia with onset of disease under 60 years of age. The clinical 
characteristics of FTLD include behavioral changes and language impairment, 
e.g. aphasia, which are accompanied by atrophy of frontal and temporal lobes. 
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Protein inclusions containing TDP-43 can often be found in cortical neurons in 
these affected regions, reminiscent of those found in motor neurons in ALS 
(reviewed in Rademakers et al, 2012). Interestingly, ALS sometimes develops 
coincidentally with FTLD; about 15% of ALS patients developed FTLD (Ringholz 
et al, 2005; Wheaton et al, 2007) and similarly, 15% of FTLD patients have 
clinical features of ALS (Ringholz et al, 2005). Therefore, these two diseases are 
often regarded as two ends of the spectrum of a single disorder. In support of this 
view, FALS-associated genes have been shown to contribute to FTLD to varied 
degrees. For instance, while mutations in TDP-43, FUS and C9orf72 are also 
found in FTLD cases, SOD1 is strictly an ALS-associated gene (Table I-2; 
reviewed in Robberecht and Philips, 2013). This variability emphasizes the 
heterogeneity of ALS-FTLD pathogenesis.  
 
1.4 What cellular and molecular mechanisms underlie ALS? 
The heterogeneity of ALS-linked gene mutations also implicates the 
diversity of molecular mechanisms that contribute to neurodegeneration (Table I-
2, reviewed in Robberecht and Philips, 2013; Peters et al, 2015). Over the past 
decades, a variety of distinct, but not mutually exclusive, cellular pathways have 
been reported to be dysfunctional or impaired in ALS models. The accountable 
mechanisms have included protein toxicity, aberrant RNA processing, 
cytoskeletal disruption, altered oxidative stress and mitochondria damage, 
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excitotoxicity, and non-cell autonomous toxicity. Mechanisms related to this 
dissertation are discussed below in more detail: 
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Proteostasis and proteinopathy 
ALS-associated mutant proteins are often misfolded and subject to 
different posttranslational modifications, e.g. ubiquitination (reviewed in 
Robberecht and Philips, 2013; Peters et al, 2015). Their clearance relies on two 
protein degradation pathways, proteasome and autophagy (reviewed in 
Tyedmers et al, 2010). Misfolded mutant proteins first form oligomeric species 
and then accumulate into aggregates. They alter proteostasis possibly through 
overwhelming the protein degradation machineries or directly inhibiting functions 
of components in the machineries. On the other hand, mutations have been 
reported in several components of ubiquitin-protesome system: VCP (Johnson et 
al, 2010) UBQLN2 (Deng et al. 2011) SQSTM1 (Fecto et al, 2011) and 
autophagy: CHMP2B (Parkinson et al, 2006), OPTN (Maruyama et al, 2010). For 
instance, ubiquilin 2 belongs to the ubiquitin-like protein family, and transports 
ubiquitinated proteins to the proteasome for degradation. Several mutations are 
identified in the gene UBQLN2 in FALS patients, and they reside in the UBA 
domain where ubiquilin 2 binds ubiquitinated proteins (Deng et al. 2011). 
Although it needs to be clarified how these mutations affects functions of 
proteasome pathways, it indicates the importance of protein quality control in the 
pathogenesis of ALS.  
Apart from compromising ubiquitin-proteasome system, ALS-linked 
mutations can cause protein toxicity through several other mechanisms. Firstly, 
the accumulation of misfolded proteins causes endoplasmic reticular (ER) stress, 
10 
 
triggers unfolded protein response (UPR), and eventually leads to cellular 
apoptosis (reviewed in Matus et al, 2013). Secondly, the presence of aggregates 
may pose a toxic effect by sequestering other cellular factors, thus impairing their 
functions. For instance, Bonetto and colleagues utilized proteomic approach to 
characterize detergent-insoluble proteins in spinal cord tissues from SOD1 G93A 
mouse models and ALS patients (Basso et al, 2009). They report that cellular 
factors important in different pathways are highly enriched in insoluble fractions 
from ALS models. This enrichment includes mitochondrial proteins, cytoskeletal 
elements, chaperones, and enzymes involved in energy metabolism, which are 
often abnormally tyrosine-nitrated. While it remains unknown as to the functional 
impacts on these sequestered proteins, their study lends support to the 
hypothesis that ALS-associated protein aggregates may cause protein toxicity 
through this gain-of-function mechanism.  
 
RNA processing  
Up to date, many RNA/DNA binding proteins have been found to 
associate with ALS (reviewed in Renton et al, 2014 and Peters at al, 2015). TDP-
43 and FUS are two most common ALS-linked RNA binding proteins, mutations 
of which account for about 4% of FALS cases. These RNA interacting proteins 
mainly localize in the nucleus, and are involved in almost every step of RNA 
processing, from transcription to mRNA splicing to micro-RNA processing. 
Mutant forms of these proteins are frequently translocated into the cytoplasm 
11 
 
(Kwiatkowski et al, 2009; Mutilac et al, 2015), raising the possibility of a loss-of-
function effect in the nucleus. However, it is also likely that these mislocalized 
proteins acquire toxic property in the cytoplasm, thereby causing a gain-of-
function outcome (reviewed in Da Cruz and Cleveland, 2011; Lee et al, 2011). 
How ALS-linked mutations affect functions of these RNA-interacting proteins is 
still inconclusive, but there is increasing evidence showing that both mechanisms 
can contribute to neurodegeneration. For instance, ALS-linked TDP-43 mutants 
have been shown to alter splicing of over 1,000 RNA transcripts in rodent models 
(Arnold et al, 2013). On the cytoplasmic side, the role of stress granules in the 
pathogenesis of ALS has been increasingly investigated in recent years. Stress 
granule is a type of ribonucleoprotein granules that assemble under cellular 
stress and sequester mRNA to maintain RNA homeostasis (Li et al, 2013). TDP-
43 has been detected in stress granules, and its ALS-linked mutants can alter 
stress dynamics (Liu-Yesucevitz et al, 2010; McDonald et al, 2011). Likewise, 
mutant forms of FUS have been shown to trans-locate to the cytoplasm, target to 
stress granules and alter their dynamics (Bosco et al, 2010; Baron et al, 2013). 
Taken together, these observations indicate that ALS-linked mutations can impair 
RNA processing at different stages and disrupt RNA homeostasis, particularly 
during cellular stress. 
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Oxidative stress 
Oxidative stress has long been considered a contributing factor to the 
pathogenesis of ALS (reviewed in Barber et al, 2006).  Clinically, increased 
oxidative stress has also been detected in ALS patients (Nagase et al, 2015). 
The first ALS-linked gene identified, SOD1, encodes superoxide dismutase 1, an 
enzyme accountable for reducing reactive oxygen species (ROS) (Fridovich, 
1986). Although most SOD1 mutations do not alter its enzyme activity (reviewed 
in Sau et al, 2007), in line with the clinical data, evidence of increased oxidative 
stress has been observed in rodent models that express ALS-linked SOD1 
mutations (Ferrante et al, 1997; Andrus et al, 1998; Liu et al, 1998). How these 
mutant proteins trigger oxidative stress is still unknown. One of the enticing 
explanations is that misfolded proteins can associate with mitochondria, the 
major site of ROS production, and cause damage to the organelle (reviewed in 
Barber et al, 2006). Indeed, abnormal neuronal mitochondria morphologies have 
been reported in various ALS models including motor neuron-like NSC-43 cell 
lines expressing mutant SOD1 (Menzies et al, 2002). Increased oxidative stress 
may further initiate a vicious cycle by damaging membrane integrity of 
mitochondria and altering protein conformation (reviewed in Barber et al, 2006). 
For instance, Bosco and colleagues have demonstrated oxidation of wild-type 
SOD1 can trigger misfolding of the protein, resulting in an aberrant conformation 
that mimics mutant SOD1 (Bosco et al, 2010). Thus altered oxidative stress can 
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be associated with both the initiation and aggravation of neurodegeneration in 
ALS.  
 
Cytoskeletal dysfunction and axonal failure 
Cytoskeleton serves as fundamental scaffold that supports axonal and 
synaptic structures and functions.  In particular, axonal transport is one of major 
neuronal functions that heavily rely on cytoskeleton, and disrupted axon transport 
involving various cargos, such as mitochondria (De Vos et al, 2007), ChAT 
(Tateno et al, 2009) and mRNA granules (Alami et al, 2014), has been reported 
in ALS models harboring SOD1 and TDP-43 mutations. Mutations of cytoskeletal 
components have also been identified as causative for FALS. For instance, 
dynactin is a protein that links cargos to the motor protein dynein, thereby 
facilitating microtubule-dependent retrograde axonal transport. Mutations in 
DCTN1, which encodes dynactin, have been reported to account for less than 
1% of FALS (Puls et al, 2003). In rodent models, these mutant dynactin have led 
to neuromuscular denervation and accumulation of vesicles in cell bodies of 
motor neurons, indicative of disrupted axonal transport (Laird et al, 2008). 
Mutations in genes encoding other cytoskeletal components including 
neurofilament heavy chain (Figlewicz et al, 1994; Al-chalabi et al, 1999) and 
peripherin (Corrado et al, 2011) have also been found in rare FALS cases. Apart 
from that, our genetic study discovered ALS-linked mutations in the PFN1 gene 
(discussed in more detail in Section I.6).  Profilin 1 is an actin-binding protein that 
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promotes actin polymerization, and throughout this dissertation, we will discuss 
the functional impacts of ALS-linked PFN1 mutations. In all, these findings 
provide strong evidence that cytoskeletal structures and functions are closely 
linked to ALS pathogenesis, and how their disruption leads to neurodegeneration 
have just started being investigated intently.  
 
1.5 How to identify gene mutations that cause FALS? 
As mentioned previously, discovery of novel gene mutations that cause 
FALS will pave the road to decipher common pathogenic mechanisms that 
underlie this devastating disease. Traditionally, linkage analysis was a standard 
method to identify gene mutations in Mendelian neurological diseases, but it has 
several limitations (reviewed in Bras et al, 2012). Firstly, it requires large multi-
generational pedigrees that contain available affected and unaffected family 
members. This usually presents difficulties in the case of rare late-onset 
neurodegenerative diseases such as ALS, for which the source of complete 
pedigrees may be limited. Secondly, complete penetrance of the disease is not 
always observed. Lastly, the genomic regions that linkage analysis identifies 
usually consist of hundreds of genes, which still require follow-up Sanger 
sequencing to precisely identify the actual mutation sites.  
With the advent of next-generation sequencing, many alternative methods 
of gene discovery have been introduced in order to uncover rare disease-linked 
mutations. In particular, exome sequencing has gained increasing popularity as a 
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cost-effective approach to identify gene mutations causative for rare neurological 
diseases including ALS (reviewed in Singleton, 2011; Bras et al, 2012).  In 
principle, amino-acid coding sequences of genomic DNA are captured by arrays 
that contain probes complementary to approximately 90% of human exome.  The 
captured DNAs then undergo next-generation sequencing and are compared 
among affected and unaffected samples. Because most ALS associated 
mutations reside within coding regions of the genome, this approach is less 
expensive than whole-genome sequencing and proves effective to identify rare 
disease-causing variants. However, exome sequencing does have its limitations. 
Since it only targets coding regions, it will not detect potential disease-linked 
mutations in non-coding regions that may be important in genetic and epigenetic 
regulation. Similarly, not all genes are captured and analyzed properly due to 
sensitivity of the arrays used and intrinsic property of the coding sequences, with 
those of high GC content being more difficult to amplify. Lastly, most variants that 
are identified in an individual sample are benign single nucleotide polymorphisms 
(SNPs). Therefore, further filtering process is needed to confirm real disease-
linked mutations. Despite these limitations, in the past few years, several novel 
ALS-causing gene mutations, such as VCP (Johnson et al, 2010) and Matrin 3 
(Johnson et al, 2014), were discovered using this approach, supporting exome 
sequencing as a useful method to investigate ALS genetics. 
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1.6 Discovery of ALS-linked mutations in the PFN1 gene 
To identify causative genes for FALS, we performed exome capture 
followed by deep sequencing on two large ALS families of Caucasian (family 1) 
and Sephardic Jewish (family 2) origin (Figure I-1A, B). Both displayed a 
dominant inheritance mode and were negative for known ALS-causing mutations, 
including the hexanucleotide repeat expansion in C9orf72 gene. For each family, 
two affected members with maximum genetic distance were selected for exome 
sequencing. To identify candidate causative mutations, variants were identified 
and filtered, as in previous exome sequencing reports (Johnson et al, 2010), 
using several criteria: the variant is observed in both family members, alters the 
amino acid sequence and is not excluded by linkage analysis. The variant is 
absent from current SNP database including dbSNP132, the 1000 Genomic 
Project (May 2011 release) or the National Heart, Lung, and Blood Institute 
(NHLBI) Exome Sequencing Project (ESP) Exome Variant Server (5,379 
sequenced exomes; http://evs.gs.washington.edu/EVS/). Remaining variants 
were confirmed by Sanger sequencing and tested for Mendelian segregation in 
all affected family members. The resulting number of candidate causative 
mutations identified was two within family 1 and three within family 2. 
Interestingly, the two families contain different mutations (C71G and M114T) 
within a single common gene: PFN1, located on chromosome 17p13.2. PFN1 is 
a 140-amino-acid protein and major growth regulator of filamentous (F)-actin 
through its binding of monomeric (G)-actin (discussed in later sections). 
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To determine whether PFN1 mutations cause familial ALS, the coding 
region was sequenced in a panel of 272 further FALS cases prescreened for 
common causative mutations. Five other familial ALS cases containing 
alterations in the PFN1 gene were identified. Interestingly, the C71G alteration 
originally identified in family 1 was discovered in two other families. For one of 
these families (family 3) (Figure I-1C), DNA was available for three other 
affected family members. Sequencing of these samples showed that the 
mutation co-segregated with ALS. A second M114T mutation was identified in an 
ALS family of Italian origin (family 4). DNA available for one sibling was shown by 
sequencing to contain this mutation. PFN1 variants were observed in two other 
FALS cases: a consecutive base-pair change (AA to GT) resulting in an E117G 
mutation, and a G-to-T transversion resulting in a G118V mutation. DNA was not 
available from other family members for these cases. Sequencing of the PFN1 
coding region in 816 sporadic ALS (SALS) samples identified two samples 
containing the E117G mutation.  
To confirm further that the newly identified variants (E117G and G118V) 
represent causal mutations, not benign polymorphisms, each was interrogated in 
the 1000 Genomes Project database and the NHLBI ESP Exome Variant Server. 
The G118V mutation was not identified in either database. However, E117G 
variant was observed in 2 samples out of 5,379 at the NHLBI ESP Exome 
Variant Server. We extended this analysis by genotyping all mutations in an 
independent set of 1,089 control samples. Three of the mutations (C71G, M114T 
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and G118V) were not observed in the 1,089 control samples; however, the 
E117G variant was observed in a single control. By combining data from the 
1000 Genome Project, the NHLBI ESP Exome Variant Server and independent 
genotyping, three of the ALS-linked variants were not present in 7,560 control 
samples, whereas the fourth (E117G) was found in 3 out of 1,090 ALS cases and 
in 3 out of 7,560 control samples. We hypothesized that the E117G variant is 
either non-pathogenic or, more likely, represents a less pathogenic mutation.  
Extending our findings, Shaw and colleagues screened 383 more ALS patients 
and concluded that E117G is a moderate risk factor for ALS (Fratta et al, 2014). 
Furthermore, another group later reported 2 more novel mutations (A20T and 
Q139L) by sequencing of a cohort of 485 ALS patients (Smith and Vance et al, 
2015). 
In total, we identified 4 mutations in 7 out of 274 FALS cases (Table I-3). 
In each case, the altered amino acid was evolutionarily conserved down to the 
level of zebrafish, supporting the possibility that these mutations are pathogenic 
(Figure I-2). The age of onset for FALS cases with PFN1 mutations is 44.8 ± 7.4. 
All PFN1 mutant cases displayed limb onset and no bulbar onset were observed, 
suggesting a common clinical phenotype among patients with PFN1 mutations.  
Taken together, our findings, along with others, suggest that mutations in 
the PFN1 gene cause about 1 % of FALS cases.  
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1.7 What is Profilin 1? 
Profilin 1 is a 140-amino-acid protein that belongs to the profilin family 
(Kwiatkowski and Bruns, 1988). It is mostly localized in the cytoplasm, although 
nuclear profilin 1 has been reported with elusive roles (reviewed in Witke, 2004). 
PFN1 is an essential gene, and its knockout in mice leads to early embryonic 
death (Witke, 2001). In mammals, there are four profilin isoforms that have been 
identified (reviewed in Birbach, 2008). Profilin 1 is expressed ubiquitously except 
in skeletal muscles, while the expression of profilin 2 is restricted to the central 
nervous system. Profilin 3 and 4 have been detected only in testis. Although 
profilin is conserved during evolution and their homologs and orthologs can be 
found in different species, homology of their primary sequences is remarkably 
low (Witke, 2004). Even different profilin isoforms within the same species are 
not highly identical (e.g. human profilin 2 is approximately 65% identical to profilin 
1). However, crystal structures of profilin resolved from different isoforms and 
species are largely superimposable (Metzler, 1995; Nodelman et al, 1999), 
indicating that conservation of profilin structures may be more critical in 
maintaining their functions than similarity of primary sequences. To further 
support this concept, Gitler and colleagues demonstrate that human profilin 1 
rescues toxic phenotype of yeast PFY null mutants despite their low sequence 
conservation (Figley et al, 2014).  
 
 
23 
 
Functions of profilin 1 
Profilin 1 is an actin binding protein, and its major function is to promote 
actin polymerization by recruiting monomeric globular (G) -actin to growing ends 
of polymeric filamentous (F) –actin (Figure I-3) (Witke, 2004). The facilitation of 
this process can be spontaneous or mediated by other actin-associated factors 
such as formin (Romero et al, 2004). Profilin 1 is also thought to facilitate the 
ADP-ATP exchange of G-actin, thus increasing G-actin pools that are readily 
available for F-actin incorporation (Mockrin and Korin, 1980). On the other hand, 
protein levels of profilin 1 seem to be critical in regulation of actin polymerization, 
as in vitro studies show that at high concentration, profilin 1 can inhibit actin 
polymerization by sequestering G-actin (Polland and Cooper, 1984).  
Apart from actin binding, profilin 1 binds phosphatidylinositide-4, 5-
bisphosphate (PI(4,5)P2) (Lassing et al, 1988; Lu et al, 1996; Lambrechts, 1997), 
suggesting it may be involved in phospholipid-mediated signaling pathway. 
Likewise, Profilin 1 also interacts with protein ligands that contain poly-L-proline 
(PLP) rich stretches (Lindberg et al, 1988; Lambrechts, 1997; Mahoney et al, 
1999). Structurally, the PLP binding motif of profilin 1 consists of its N- and C-
terminal helices and is separated from its actin binding domain by a central β-
sheet, while PI(4,5)P2 binding motif partially overlaps with the actin binding 
domain (Figure I-4). Up to date, more than 50 cellular ligands have been 
reported to contain PLP rich stretches and to interact with profilin 1 (Table I-4). 
They are involved in various actin-dependent and actin-independent cellular 
24 
 
pathways. Most of these interactions were reported in vitro, and their 
physiological roles have yet to be elucidated. Nevertheless, the diversity of this 
interaction profile indicates that profilin 1 has multi-functional roles in regulating 
different cellular pathways. 
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1.8 What does profilin 1 do in neurons? 
Neuronal localization of profilin  
Actin cytoskeleton provides a crucial scaffolding network in both 
presynaptic and postsynaptic neurons (reviewed in Cingolani and Goda, 2008). 
For instance, it contributes to the maintenance of synaptic vesicle machinery 
(presynaptically) and distribution of neurotransmitter receptors (post-
synaptically). Given its association with actin, the role of profilin in the regulation 
of neuronal cytoskeleton has long been discussed. Studies have demonstrated 
that profilin 1 is present in both presynaptic (Faivre-Sarrailh et al, 1993) and 
postsynaptic regions (Giesemann et al, 2003). It interacts with corresponding 
scaffolding proteins including presynaptic aczonin (Wang et al, 1999) and 
postsynaptic gephyrin and drebrin (Mammoto et al, 1998), thus implying its 
involvement in synaptic actin network.  
 
Role of profilin in axonal outgrowth 
Furthermore, in drosophila embryo, null mutants of profilin leads to 
arrested axonal outgrowth in motor neurons (Wills et al, 1999). Similarly, in mice, 
Mammalian enabled (Mena), a PLP rich ligand, is shown to interact with profilin 
1, and Mena deficiency leads to defects in axonal pathfinding at embryonic 
stage. This possibly acts through regulation of profilin 1 because Mena-deficient 
mice heterozygous for profilin 1 show severe defects in neurulation (Lanier et al, 
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1999). These data indicate that profilin 1 is important for correct axonal path 
finding during development. It has also been suggested that different binding 
motifs of profilin 1 affect neuritogenesis in specific ways. Ampe and colleagues 
proposed this notion by studying neuritogenesis in PC12 cells, a cell line derived 
from rate pheochromocytoma (Lambrechts et a, 2006). They found that while 
actin binding-defective profilin 1 mutant reduced neurite length and filopodia 
formation, PLP binding-defective mutants led to longer and more branched 
neurites. On the other hand, Dotti and colleagues showed that profilin 2 
negatively regulated neurite outgrowth in rat hippocampal neurons, which was 
dependent on the Rho/ROCK pathway (Silva et al, 2003). Taken together, these 
studies emphasize the complexity in profilin-mediated neurite outgrowth.  
 
Role of profilin in postsynaptic actin network  
Several studies have also investigated postsynaptic roles of profilin. 
Presynaptic glutamate and electrical stimulations induce targeting of profilin 2 to 
dendritic spines of hippocampal neurons (Ackermann et al, 2003). Blocking this 
targeting process destabilizes their structures. Likewise, potassium chloride 
treatment of primary hippocampal neurons leads to a similar effect by recruiting 
profilin 1 into dendritic spine regions (Neuhoff et al, 2005). These findings imply 
that profilin may regulate postsynaptic actin dynamics in an activity-controlled 
manner. Interestingly, it has also been shown that behavioral paradigms such as 
fear conditioning result in enrichment of profilin in dendritic spines in the lateral 
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amygdala, thereby altering their structures (Lamprecht et al, 2006). This study 
further supports the hypothesis that distribution of profilin in dendritic spines has 
regulatory effects in important neuronal functions such as learning and memory.  
 
Profilin 1 vs. profilin 2 
It is intriguing that there are two profilin isoforms, profilin 1 and 2, 
coexisting in the central nervous system. Both isoforms are detected in 
presynaptic, and more abundantly, postsynaptic regions (Murk et al, 2012). 
However, they respond differently to activity manipulation. In cultured rat 
hippocampal neurons, pharmacological inhibition of NMDA receptors leads to 
reduction of synaptic profilin 2, while profilin 1 is spared. On the other hand, 
neuronal stimulation by brain derived neurotrophic factor (BDNF) increases 
profilin 1 level to a greater degree than profilin 2 (Murk et al, 2012). 
Biochemically, mass spectrometric study of mouse brain extracts also shows that 
proteins interacting with profilin 1 and 2 do not fully overlap (Witke et al, 1998). 
Likewise, proflin 1 is also shown to have higher affinity to actin than profilin 2 
(Giesselmann et al, 1995). Functionally, in hippocampal neurons, profilin 1 
cannot fully rescue dendritic abnormalities caused by profilin 2 knockdown 
(Michaelsen et al, 2010). Taken together, these findings suggest that in the 
central nervous system, profilin 1 may have distinct functions that cannot be fully 
replaced by profilin 2, and vice versa. 
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1.9 Profilin and neurodegeneration 
Spinal muscular atrophy (SMA)  
SMA is a common autosomal recessive neurological disorder, 
characterized by loss of motor neurons in the spinal cord and brain stem. It is 
caused by deletion or missense mutations in the survival of motoneuron 1 
(SMN1) gene that encodes SMN (Brzustowicz et al, 1990). SMN is present both 
in the nucleus and the cytoplasm. Nuclear SMN localizes within nuclear foci 
called “gems” (Liu et al, 1996); it is involved in multiple pathways including RNA 
processing and is required for normal motor neuron development.  Notably, SMN 
protein contains a PLP rich motif (Giessemann et al, 1999) and has been shown 
to interact with profilin (Witke et al, 1998). In particular, profilin 2 has much higher 
affinity to SMN than profilin 1. They also demonstrate subcellular co-localization, 
and this interaction is abolished by SMA-linked missense mutations and 
deletions (Sharma et al, 2005). On a molecular level, knockdown of SMN leads 
to hyperphosphorylation of profilin through action of Rho-kinase (ROCK), and 
phospho-mimic mutant of profilin 2 reduces neurite outgrowth in PC12 cell 
models (Bowerman et al, 2007). Notably, increased F-actin/G-actin ratio is also 
detected in primary motor neurons derived from SMA mouse models (Nöll et al, 
2011). Taken together, these studies demonstrate that SMN deficiency can 
cause alteration of actin cytoskeleton and eventually abnormal neurite extension 
through dysregulation of profilin 2.  It also highlights the contribution of profilin to 
motor neuron integrity.  
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Huntington’s disease 
Huntington’s disease is another common neurodegenerative disorder 
caused by polyglutamine (polyQ) expansion in the huntingtin protein (Walker, 
2007). The expanded huntingtin tends to form aggregates and presents 
cytotoxicity that leads to neurodegeneration (Rubinsztein, 2003).  Interestingly, 
huntingtin also has PLP binding motifs and is an interacting partner of profilin 
(Witke et al, 1996).  In cultured cells, overexpression of profilin 1 reduces 
huntingtin aggregation (Bauer et al, 2009), and this effect requires its actin 
binding activity (Shao et al, 2008). Hyperphosphorylation of profilin by ROCK 
negatively regulates both its ability to bind actin and to reduce huntingtin 
aggregates (Shao et al, 2008). On the other hand, another study showed that 
expanded polyQ tracts promote degradation of profilin through ubiquitin-
proteasome system (Burnett et al, 2008). In line with other reports, this study also 
demonstrated that overexpression of profilin mitigates polyQ-induced cellular 
toxicity in both cellular and Drosophila models (Burnett et al, 2008). These data 
imply the interaction between huntingtin and profilin has reciprocal modulatory 
effects. They also lend support to the hypothesis that profilin plays a regulatory 
role in aggregate formation in neurodegenerative diseases.  
 
ALS 
As stated in earlier sections, stress granules are important coping 
machinery during cellular stress (Li et al, 2013), and altered stress granule 
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dynamics have been associated with ALS (Baron et al, 2013). Notably, Gitler and 
colleagues reported that profilin 1 is associated with stress granules in primary 
cortical neurons and multiple cell lines, and ALS-linked profilin 1 mutants fail to 
be targeted into oxidative stress-induced stress granules (Figley et al, 2014). 
This observation indicates that profilin 1 may engage in maintenance of RNA 
homeostasis through regulating stress granule dynamics.  
 
1.10 Summary 
ALS is a devastating neurodegenerative disease with varied gene 
etiology. By using exome-sequencing methods, we identified mutations C71G, 
M114T, E117G, and G118V in the PFN1 gene. How these mutations alter 
functions of profilin 1 and lead to neurodegeneration is still unknown. The work 
presented in this dissertation aims to characterize the neuronal impacts of ALS-
linked PFN1 mutations and to elucidate underlying mechanisms using in vitro 
cellular and in vivo Drosophila models. Chapter II investigates affinity to actin and 
propensity to aggregate of ALS-linked profilin 1 mutants in mammalian cultured 
cells. In this chapter, co-immunoprecipitation studies demonstrate that mutant 
profilin 1 reduce affinity to actin and immunofluorescence in primary motor 
neurons confirms reduced F-actin/G-actin ratio, indicative of a loss-of-function 
mechanism. Molecular solubility analysis and immunofluorescence show mutant 
profilin 1 form ubiquitinated aggregates, which is enhanced by proteasome 
inhibition. Overexpression of mutant profilin 1 in primary motor neurons also 
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reduces axonal length and growth cone area, supporting their deleterious effects 
on neuronal morphologies. Chapter III introduces a novel Drosophila model 
overexpressing PFN1 to further characterize these mutations in vivo. In this 
Chapter, immunohistochemistry of larval neuromuscular junctions (NMJs) 
demonstrates that profilin 1 overexpression promotes formation of filopodia 
without altering overall structure of NMJs. In this analysis, M114T has less 
filopodia formation compared to WT profilin 1. Behavioral analyses then reveal 
that profilin 1 overexpression leads to adult-onset locomotion defects. 
Combination of immunohistochemical and behavioral approaches spanning 
different developmental stages corroborates the hypothesis that ALS-linked 
PFN1 mutations have a loss-of-function effect on F-actin formation. Collectively, 
the work presented in this dissertation sheds light on largely elusive PFN1-
associated ALS pathogenesis, by demonstrating aggregation of mutant profilin1 
in vitro and, more importantly, a loss-of-function mechanism in actin 
polymerization in vitro and in vivo. The findings in this novel Drosophila model 
also lay the groundwork for future genetic screens to uncover other cellular 
pathways affected by mutant profilin 1.  
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PREFACE TO CHAPTER II: 
 
Chi-Hong Wu performed the experiments presented in this Chapter with the 
following exceptions:  
 
Claudia Fallini performed all experiments on primary motor neurons. 
Immunohistochemistry of human tissues were performed at the Emory University 
Neuropathology Core (with the assistance of Marla Gearing and Deborah 
Cooper). 
 
The work presented in this Chapter aimed to characterize novel PFN1 mutations 
causative for FALS. All data were published with the exception of Figure 6, 
Figure 7C and Figure 9C.    
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CHAPTER II: CHARACTERIZATION OF ALS-LINKED PFN1 MUTATIONS 
IN VITRO 
 
2.1 Introduction 
By using exome-sequencing, we identified C71G, M114T, E117G and 
G118V mutations in the PFN1 gene that contribute to about 1% of FALS cases. 
Profilin 1 is a small actin-binding protein of about 15 kDa. It localizes mostly in 
the cytoplasm and is ubiquitously expressed except in skeletal muscles 
(reviewed in Witke, 2004). The major function of profilin 1 is to promote actin 
polymerization by binding monomeric G-actin and delivering them to the growing 
ends of polymeric F-actin. In vitro studies show that proflin 1 also interacts with 
phosphatidylinositide-4, 5-bisphosphate (PI(4,5)P2) (Lassing et al, 1988; Lu et al, 
1996; Lambrechts, 1997) and cellular ligands containing poly-L-proline (PLP) rich 
stretches (Lindberg et al, 1988; Lambrechts, 1997; Mahoney et al, 1999; Witke, 
2004), suggesting it functions in various cellular pathways. Profilin regulates the 
neuronal cytoskeleton and is crucial in maintaining multiple aspects of neuronal 
functions (reviewed in Birbach, 2008). For example, alteration of its expression 
leads to arrested axonal outgrowth and incorrect axon pathfinding in embryonic 
Drosophila and rodent models (Lanier et al, 1999; Wiils et al, 1999). Likewise, 
profilin interacts with various scaffolding proteins in synaptic regions (Giesemann 
et al, 2003), and is recruited to dendritic spines in an activity-regulated manner, 
suggesting a role in the regulation of postsynaptic activities (Ackermann and 
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Matus, 2003). Witke and colleagues also demonstrated that profilin depletion 
alters synaptic vesicle exocytosis, thereby affecting synaptic transmission (Pilo 
Boyl et al, 2007). Nonetheless, how ALS-linked PFN1 mutations affect functions 
of profilin 1 on a molecular and cellular level is still unknown.  
Ubiquitinated aggregates are histopathological hallmarks of ALS. These 
aggregates (Kanning et al, 2010), which localize in affected motor neurons, 
consist of misfolded proteins that harbor ALS-linked mutations. In many cases, 
they also contain phosphorylated TDP-43 (Neumann et al, 2006). It is unknown 
whether PFN1 mutations also increase its propensity to aggregate.  
To investigate if mutant PFN1 form aggregates, we first transfected wild-
type or mutant PFN1 in cultured mammalian cells including neuroblastoma-2A 
(N2A) cell line and primary motor neurons. We then used this system to measure 
protein solubility by molecular solubility analysis and immunofluorescence. To 
elucidate if PFN1 mutations lead to a loss of function in actin polymerization, we 
first performed co-immunoprecipitation to test the interaction between actin and 
PFN1. We then extended this experiment by transfecting primary motor neurons 
with wild-type or mutant PFN1 and measuring F-actin/G-actin ratio. Lastly, to test 
if mutant PFN1 impair neuronal morphologies, we again transfected primary 
motor neurons with wild-type or mutant PFN1 and measured axonal outgrowth 
and area of growth cones.  
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2.2 Results 
Mutant PFN1 form insoluble aggregates. 
To investigate whether the observed PFN1 mutants form insoluble 
aggregates, Western blot analysis of NP-40-soluble and insoluble fractions was 
performed on Neuro-2A (N2A) cells transfected with wild-type or one of the four 
PFN1 mutants. PFN1 protein was present predominantly in the soluble fraction of 
cells transfected with the wild-type construct as compared with the insoluble 
fraction. Conversely, a considerable proportion of the C71G, M114T and G118V 
mutant proteins were detected in the insoluble fraction (Figure II-1A). 
Furthermore, several higher molecular mass species were observed, indicative of 
SDS-resistant PFN1 oligomers. However, the E117G mutant displayed a pattern 
more similar to wild-type PFN1 with most of the expressed protein in the soluble 
fraction. Differential expression of PFN1 constructs was ruled out by Western blot 
analysis of whole cell lysates (Figure II-1B). Analysis of lymphoblast cell lines 
derived from affected and unaffected members of the ALS family harboring C71G 
mutation did not display any difference in PFN1 protein solubility (Figure II-1C). 
Autopsy material was not available for any affected individual.  
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Mutant PFN1 form ubiquitinated aggregates in cultured cells.  
We extended these observations by staining the PFN1 protein in 
transfected cells. Wild-type PFN1 exhibited a diffuse cytoplasmic expression 
pattern in transfected N2A cells, as previously reported (Suetsugu et al, 1998). 
By contrast, ALS-linked PFN1 mutants often assembled into cytoplasmic 
aggregates (Figure II-2A).  In this experiment, cytoplasmic V5-staining positive 
granules with concentrated fluorescence intensity that constained with ubiquitin 
were defined as aggregates. Image analysis determined that 15-61% of mutant-
expressing cells contain cytoplasmic aggregates (Figure II-2B), including the 
E117G mutant, which showed minimal insoluble PFN1 protein by Western blot 
analysis. No aggregates were observed for cells expressing wild-type PFN1. Co-
staining revealed that these aggregates were also ubiquitinated. Primary motor 
neurons (PMNs) expressing the C71G, M114T and G118V mutants similarly 
demonstrated ubiquitinated aggregates, albeit at a lower percentage; aggregates 
were not observed in cells expressing the E117G mutant or wild-type PFN1 
(Figure II-2C). Immunoprecipitation of the PFN1 protein followed by Western blot 
analysis confirmed the insoluble mutant PFN1 protein is poly-ubiquitinated 
(Figure II-2D).  
Proteasome inhibition enhances aggregate formation by mutant PFN1.  
To determine whether ubiquitin-proteasome system impairment causes 
accumulation of mutant PFN1 aggregates, transfected N2A cells were exposed 
to the proteasome inhibitor MG132. ALS-linked PFN1 mutants, including E117G, 
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showed increased insoluble protein levels and increased levels of higher 
molecular mass species by Western blot analysis (Figure II-3A). Minimal 
insoluble protein was observed for the wild-type PFN1. PFN1 staining in N2A 
cells confirmed these results (Figure II-3B). Cells expressing C71G, M114T and 
G118V mutant PFN1 had numerous, large aggregates after MG132 treatment.  
E117G mutants showed a moderate aggregate level, and the wild-type PFN1 
displayed minimal levels.    
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Figure II-2. Mutant PFN1 produces ubiquitinated insoluble aggregates.   
 
N2A cells (A) and PMNs (C) were transfected with constructs expressing either 
wild-type or mutant V5-PFN1. The PMNs were additionally co-transfected with a 
HA-ubiquitin expressing construct. The cells were then fixed and stained with 
antibodies directed against V5, HA (PMNs) and ubiquitin (N2A). Examples of 
aggregates, indicated by arrows, are enlarged in the inset in (C). Scale bar: 5 µm 
(A), 10 µm (C). (B) Transfected N2A cells displaying insoluble aggregates were 
counted using the software package MetaMorph. Comparisons were made using 
one-way ANOVA testing with Dunnett’s multiple test comparison. *P<0.05, 
***P<0.001, n.s. P>0.05. Error bars indicate SEM. (D) Insoluble mutant PFN1 is 
polyubiquitinated. N2A cells were transfected with control vector (lanes 3, 4, 
9,10), V5-PFN1-C71G (lanes 5, 6, 11, 12) and a HA-tagged Ubiquitin expressing 
vector (lanes 3-6, 9-12). The cells were treated with (lanes 2, 4, 6, 8, 10, 12) and 
without (lanes 1, 3, 5, 7, 9, 11) the proteasome inhibitor MG132. The cells were 
then lysed and NP-40 soluble (lanes 1-6) and insoluble (lanes 7-12) fractions 
were isolated and immunoprecipitated with a V5 antibody. The 
immunoprecipitates were separated by SDS-PAGE and then immunoblotted with 
antibodies for either V5 or HA, as indicated.  
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PFN1 aggregates sequester TDP-43.  
Given the propensity of mutant PFN1 to form aggregates, we investigated 
whether other ALS-related proteins may be present within these aggregates. 
Thus, we transfected PMNs with mutant PFN1 and tested for co-aggregation of 
the ALS-related proteins FUS and TDP-43. Furthermore, we also tested for 
aggregation of the SMA-related protein SMN owing to its ability to bind PFN1 
(Giesemann et al, 1999). About 30-40% of cells contained cytoplasmic PFN1 
aggregates co-stained with TDP-43 (Figure II-4A). However, no co-aggregation 
of either FUS or SMN with mutant PFN1 was observed (Figure II-4B,C). These 
results suggest that mutant PFN1 may contribute to ALS pathogenesis by 
inducing aggregation of TDP-43. On the basis of these observations, we 
investigated whether aggregates of TDP-43 contain PFN1 by staining spinal cord 
tissues from 18 SALS cases displaying TDP-43 pathology and 6 non-ALS 
controls without TDP-43 pathology. Abnormal PFN1 pathology was not 
discovered in SALS cases, suggesting that TDP-43 aggregation does not induce 
PFN1 aggregation (Figure II-5A). Expression of carboxyl-terminal fragment of 
TDP-43, which produces insoluble aggregates, in PMNs also failed to co-
aggregate with wild-type PFN1, thus supporting this observation (Figure II-5B).  
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PFN1 aggregates did not sequester wild-type PFN1.  
The propensity of mutant PFN1 to aggregate also raises the possibility 
that it may pose a gain-of-function mechanism by sequestering wild-type PFN1 
into aggregates, thereby interfering with their cellular functions. To test this 
hypothesis, a V5-tagged wild-type PFN1 construct and a HA-tagged C71G PFN1 
construct were co-transfected in N2A cells. Cellular staining showed that wild-
type PFN1 remained diffuse in the cytoplasm and depleted from the aggregates 
formed by C71G PFN1 (Figure II-6A). To exclude the effect of different tags on 
aggregation, a V5-tagged C71G PFN1 construct was co-transfected with HA-
tagged C71G construct. The staining result showed that C71G PFN1 tagged with 
V5 and HA epitopes co-aggregated (Figure II-6B). These observations indicate 
that aggregates formed by mutant PFN1 do not sequester wild-type PFN1. 
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Mutant PFN1 have reduced affinity to actin.  
Evaluation of the profilin 1-actin complex crystal structure showed that all 
ALS-linked mutations lie in close proximity to the actin-binding residues of profilin 
1 (Schutt et al, 1993; Figure II-7A). Therefore, we investigated whether the ALS-
linked mutations display a decreased level of bound actin. Towards this end, we 
performed immunoprecipitation and Western blot analysis of cells transfected 
with wild-type and mutant PFN1. As a control, we also transfected cells with a 
construct expressing a synthetic profilin 1 (H120E) mutant protein. This alteration 
is located at a crucial residue previously shown to abolish PFN1 binding to actin 
(Suetsugu et al, 1998). We observed that C71G, M114T, G118V and H120E 
mutants, but not the E117G, had reduced levels of bound actin relative to wild-
type PFN1 (Figure II-7B). Apart from actin, we also wondered if ALS-linked 
PFN1 mutations disrupted interaction with other cellular factors such as PLP 
ligands. We chose to test mDia1, a PLP ligand that coordinates with PFN1 to 
facilitate actin polymerization (Watanabe et al, 1997). Co-immunoprecipitation 
showed that PFN1 C71G had reduced interaction with mDia1 (Figure II-7C). This 
interaction did not seem to depend on affinity to actin, because PFN1 H120E, the 
actin binding-defective mutant, still maintained its interaction with mDia1. This 
result suggests that PFN1 C71G may affect actin polymerization through 
interfering with multiple cellular factors.  
 
51 
 
Mutant PFN1 lead to collapsed growth cones and reduced F-actin/G-actin ratio in 
primary motor neurons.  
The regulation of actin dynamics in the growth cone is necessary for axon 
outgrowth. To determine whether ALS-linked PFN1 mutants have a similar 
phenotype, PMNs transfected with wild-type and two mutant PFN1 constructs 
(C71G and G118V) were stained to detect F- and G-actin localization patterns in 
the highly dynamic and actin-rich growth cone (Figure II-8A). PFN1 mutant 
expression in PMNs led to a significantly reduced growth cone size (~43-52%) 
relative to wild-type PFN1 (Figure II-8B). Also, mutant PFN1 expression 
significantly altered growth cone morphology. In wild-type PFN1-expressing cells, 
growth cones had elaborate structures with several F-actin rich filopodia, 
whereas virtually no filopodia were visible in the mutant PFN1 growth cones. 
Similar results were observed for the synthetic H120E mutant defective in actin 
binding. The growth cones in mutant-expressing PMNs also had a lower ratio of 
F/G-actin relative to wild-type-expressing PMNs. In particular, the C71G mutant-
expressing PMNs displayed an F/G-actin ratio 24.4% of the wild-type expressing 
PMNs (Figure II-8C). These results suggest that mutant PFN1 are less efficient 
in the conversion of G-actin to F-actin within the growth cone region, thus 
affecting its morphology.  
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Mutant PFN1 lead to shortened axon outgrowth in primary motor neurons.  
Previous reports have shown that PFN1 alterations inhibit neurite 
outgrowth (Suetsugu et al, 1998; Wills et al, 1999). We thus investigated whether 
ALS-linked PFN1 mutants inhibit neurite outgrowth by measuring axonal length in 
PMNs transfected with wild-type or mutant PFN1. As a positive control, we also 
transfected PMNs with the H120E-expressing construct. In addition to lacking 
actin-binding ability, H120E protein inhibits neurite outgrowth (Suetsugu et al). As 
expected, the H120E-expressing cells displayed a pronounced decrease in axon 
length relative to the wild-type construct. Three ALS-linked PFN1 mutations 
(C71G, M114T and G118V) also showed a significant decrease in axon 
outgrowth. In particular, the G118V-associated reduction is similar to that 
observed with H120E construct. Axon outgrowth inhibition was observed with the 
E117G mutant but did not reach statistical significance (Figure II-9A,B). There 
results suggest that mutations in PFN1 may contribute to ALS pathogenicity in 
part by inhibiting axon dynamics.  
 
Mutant PFN1 do not increase cell death in HEK293 cells. 
To determine if mutant PFN1 affect cell viability, HEK293 cells (derived 
from human embryonic kidney cells), were transfected with WT and mutant 
PFN1, and subject to LDH membrane integrity analysis 24 hours after 
transfection. Lactate dehydrogenase (LDH) is a cytosolic enzyme that is released 
when integrity of cellular membrane is compromised. It can therefore be used as 
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an indicator for increased cell death. When compared with control cells, no 
increase in LDH level in the medium was detected from cells transfected with 
either wild-type or C71G PFN1 (Figure II-9C). This result suggests mutant PFN1 
does not lead to immediate cell death under these conditions, and its lethal 
effects may require longer time to manifest. 
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2.3 Discussion 
In this Chapter, we characterized functional impacts of novel ALS-linked 
mutations in the PFN1 gene. Molecular solubility analysis showed that mutations 
C71G, M114T and G118V led to the presence of mutant PFN1 in NP-40 resistant 
fractions, while wild-type PFN1 remained in NP-40 soluble fractions. 
Immunofluorescence confirmed that mutant PFN1 formed ubiquitinated 
aggregates in N2A cells and primary motor neurons. Pharmacological inhibition 
of proteasome further enhanced aggregate formation both in solubility test and 
cellular staining. These results indicate mutant PFN1 has higher propensity to 
aggregate, similar to other ALS-linked mutant proteins. Bosco and colleagues 
later conducted in vitro chemical and thermal denaturation analyses of 
recombinant mutant PFN1 and confirmed that ALS-linked mutations destabilize 
PFN1 (Boopathy et al, 2014). X-ray crystallography of M114T PFN1 further 
revealed that the destabilization is induced by a moderate structural change 
(Boopathy et al, 2014). This observation thus provides further evidence that ALS-
linked mutations induces PFN1 aggregation. 
Contrary to other mutants, our solubility analysis and cell staining showed 
that E117G variant acts similar to wild-type PFN1, with minimal NP-40 insoluble 
fractions and aggregate formation. Nonetheless, when proteasome was inhibited, 
E117G variant resulted in more prominent aggregate formation than wild-type 
PFN1. This was consistent with Bosco and colleagues’ study where E117G only 
has moderate destabilizing effects compared with other ALS-linked PFN1 
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mutants (Boopathy et al, 2014). It is noteworthy that this variant was also 
detected in SALS patients and controls. Therefore, these data support the notion 
that E117G is an ALS-associated risk factor (Fratta et al, 2014) and 
manifestation of its toxicity may require secondary impairment of other cellular 
factors, such as proteasome inhibition. The observation that E117G maintains 
affinity to actin also raises the possibility that it may affect other actin-
independent functions. 
We then determined if PFN1 aggregates sequestered other cellular 
factors, thereby resulting in a gain-of-function effect. We did not detect 
sequestration of SMN, FUS and wild-type PFN1. However, ~30-40% of cells 
containing cytoplasmic PFN1 aggregates co-stained with TDP-43.  We also 
stained spinal cord tissues from SALS patients displaying TDP-43 pathology and 
expressed carboxyl-terminal fragment of TDP-43, which produces insoluble 
aggregates, in PMNs. Both of these approaches failed to detect co-staining of 
PFN1 in TDP-43 aggregates.  These results suggest that TDP-43 aggregation 
induced by mutant PFN1 is specific and PFN1 may contribute to ALS 
pathogenesis via a gain-of–function mechanism by inducing aggregation of TDP-
43.  
We also wondered whether ubiquitinated aggregates could be detected in 
ALS patients harboring PFN1 mutations.  Solubility analysis of lymphoblast cells 
derived from ALS patients harboring C71G mutations showed no increase in 
insoluble PFN1 fractions compared to controls. We argue that the inherent 
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cellular environments for proteostasis may differ in central nervous system and 
immune system, and a “second-hit” factor, such as oxidative stress and 
dysfunctional protein clearance machinery, may be required for protein 
aggregates to form. With the advent of inducible pluripotent stem cells and 
CRSIPR genomic editing, it will be possible in the near future to confirm this cell-
type specific vulnerability. We also attempted to determine if mutant PFN1 
increased cell death by measuring LDH release. In this assay, no increase in 
LDH levels was detected in cells transfected with mutant PFN1. Because in this 
experiment we used HEK293 cells, a non-neuronal cell line, to achieve higher 
transfection efficiency, the absence of increased cell death may still be due to 
differential cell-type vulnerability. Because ALS is an adult-onset progressive 
neurodegenerative disease, it is also plausible that the expression of mutant 
PFN1 may not cause immediate cell death, but accumulate its toxicity over time.  
The major function of PFN1is to promote actin polymerization and crystal 
structure of profilin 1-actin complex reveals that ALS-linked residues are in close 
proximity to actin binding sites. Therefore, we tested if ALS-linked mutations 
would affect actin polymerization. Co-immunoprecipitation in high-salt buffers 
showed that all ALS-linked variants except for E117G had reduced affinity to 
actin. When expressed in primary motor neurons, mutant PFN1 also led to 
reduced F-actin/G-actin ratio in grown cones, indicating impaired actin 
polymerization. Taken together, our results suggest a loss of function effect on 
actin polymerization particularly in axonal termini. On the other hand, Bosco and 
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colleagues’ in vitro actin affinity analysis showed no difference in actin binding 
among wild-type and mutant PFN1 (Boopathy et al, 2014). Their analysis was 
based on the observation that at high concentration, PFN1 can sequester G-actin 
and inhibit spontaneous actin nucleation (Polland and Cooper, 1984). PFN1 
concentration-dependent suppression of actin polymerization was thus measured 
to indirectly indicate its affinity to G-actin. Nonetheless, in cellular environments, 
many factors, such as formin, can interact and coordinate with PFN1 to facilitate 
actin polymerization (Romero et al, 2004). Therefore this discrepancy raises the 
possibility that mutant PFN1 may impair actin polymerization and dynamics 
through aberrant interactions with other protein components of actin 
cytoskeleton. To support this hypothesis, our co-immunoprecipitation showed 
that at least PFN1 C71G reduces its interaction with mDia1, a formin isoform that 
mediates actin polymerization. Because this interaction does not depend on 
affinity to actin, it remains unclear whether this disruption is due to loss of 
interaction with PLP stretches or due to conformational changes that alter affinity 
to specific proteins. Nonetheless, our data indicate ALS-linked PFN1 mutants 
can affect actin polymerization through multiple mechanisms.  
The actin cytoskeleton plays an important role in multiple aspects of 
neuronal functions including axon outgrowth and synaptic integrity (Luo, 2002). 
Thus we asked if mutant PFN1 would impair neuronal morphologies. 
Overexpression of ALS-linked PFN1 variants in primary motor neurons resulted 
in shorter axons and collapsed growth cones. This is likely to be caused by 
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altered actin dynamics in the grown cone through a loss-of-function mechanism. 
However, we cannot exclude the contribution of gain-of-function toxic effects of 
PFN1 aggregates, possibly by sequestering other cellular factors or 
overwhelming the ubiquitin-proteasome system. Since PFN1 has a variety of 
interacting factors other than G-actin (reviewed in Witke, 2004), it is also possible 
that ALS-linked mutations may affect other actin-independent pathways that lead 
to neuronal defects. While further work is required to clarify the contribution of 
each pathway, our findings are significant in that they demonstrate the relevance 
of ALS-linked PFN1 mutations to neurodegeneration. Although neuritogenesis is 
an early developmental event, axon outgrowth also occurs during re-innervation 
(reviewed in Harel and Strittmatter, 2006; Bradke et al, 2012). Alteration of this 
process may promote neurodegeneration secondary to axonal injury or other 
degenerating stimuli. Furthermore, the “dying-back” hypothesis suggests 
degenerating mechanisms may be initiated focally in the axonal and synaptic 
regions (reviewed in Moloney et al, 2014). Maintenance of structures and 
functions in these regions rely heavily on intact actin dynamics. Our observation 
that mutant PFN1 reduce F-actin/G-actin ratio in axonal termini supports the 
possibility that ALS-linked mutations may disrupt axonal and synaptic functions 
by altering local actin dynamics.   
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2.5 Material and methods 
Cell culture and transfections of N2A cells 
N2A cells were maintained in MEM with 10% fetal bovine serum, 2 mM L-
glutamine and 100 U penicillin per 100 µg streptomycin at 5% CO2. For cell lysis 
and western blot analyses, transfections were performed in 6-well plates with 
4 µg of plasmid DNA using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s protocol. For immunofluorescence, cells were plated onto 12-mm 
round coverslips in 24-well plates and transfected with 0.8 µg of DNA. 
Immunofluorescence of N2A cells 
Immunofluorescence was performed as previously described (Bosco et al, 2010) 
In brief, at 48 h after transfection, cells were fixed with 4% paraformaldehyde at 
room temperature for 15 min, permeabilized with 1% Triton X-100 at room 
temperature for 10 min, and then blocked with blocking buffer (50 mM NH4Cl, 
10 mg ml−1 BSA, 2% natural goat serum, 0.1% Triton X-100 in Dulbecco’s PBS) 
at 37 °C for 1 h. Appropriate fluorophore-conjugated antibody was diluted in 
63 
 
dilution buffer (0.1% Triton X-100, 0.15% goat serum in Dulbecco’s PBS) and 
added at 4 °C overnight. After three washes with PBST (0.1% Tween-20), cells 
were mounted with Vectashield Hard Set Mounting Medium containing DAPI 
(Vector Laboratories). Confocal images were obtained with a ×100 Plan Apo oil 
objective lens on a Nikon TE-2000E2 inverted microscope (Nikon Instruments) 
with a Yokogawa CSU10 Spinning Disk Confocal Scan Head (Solamere 
Technology Group) and processed with ImageJ software. For confocal imaging, 
mouse Dylight 549-V5 antibody (1:100, AbDserotec) and rabbit Dylight 488-
ubiquitin antibody (1:100, Enzo Life Sciences) were used. For aggregate 
counting, mouse Alexa Fluor 488-V5 antibody (1:100, AbDserotec) was used. To 
count the number of cells containing insoluble aggregates, images were obtained 
with a Zeiss Axioskop 2 microscope with a ×100 objective. The images were 
processed with MetaMorph (v.7.5, Molecular Devices) image analysis software. 
Fractionation of insoluble/soluble PFN1 and western blotting 
Transfected cells were washed with cold PBS and then scraped directly in NP-40 
lysis buffer (1% NP-40, 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 10% 
glycerol, 1 mM dithiothreitol (DTT), 10 mM sodium fluoride, 1 mM sodium 
orthovanadate and 5 mM sodium pyrophosphate) with EDTA-free protease 
inhibitors (Roche). The lysates were rotated for 30 min at 4 °C followed by 
centrifugation at 15,800g for 20 min. The supernatant was removed and used as 
the soluble fraction. To remove carryovers, the pellet was washed with lysis 
buffer, and then resuspended in urea-SDS buffer (NP-40 lysis buffer with 8 M 
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urea, 3% SDS) followed by sonication. The lysate was then spun again for 20 min 
at 4 °C and the supernatant was removed (insoluble fraction). Protein 
concentrations were determined by the BCA assay. Western blot detection was 
performed on Odyssey Infrared Imager (Li-Cor Biosciences). Antibodies for 
Western blotting are as follows: mouse monoclonal anti-GAPDH (1:1,000, 
Sigma-Aldrich); mouse monoclonal anti-V5 (1:2,000, Invitrogen); polyclonal 
IRDye 800CW goat anti-mouse IgG (1:8,000, LI-COR); polyclonal IRDye 680 
goat anti-rabbit IgG (1:8,000, LI-COR); and polyclonal IRDye 800CW goat anti-
rabbit IgG (1:8,000, LI-COR). To inhibit proteasome activity in N2A cells, cells 
were incubated with 10 µM MG132 (Sigma-Aldrich) after transfection for 16 h 
before collection. 
Immunoprecipitations 
V5–PFN1-transfected HEK293 cells were lysed at 24 h with RIPA buffer (150 mM 
NaCl, 50 mM Tris-HCl, pH 7.5, 1% NP40, 0.1% SDS, 0.5% sodium deoxycholate, 
5 mM EDTA, 10 mM sodium fluoride, 1 mM sodium orthovanadate and 1× 
protease inhibitor cocktail). The lysates were precleared with Dynabeads Protein 
G (Invitrogen) followed by immunoprecipitation with 1 µg anti-V5 antibody at 4 °C 
overnight followed by incubation with Dynabeads Protein G for 1 h. The protein–
bead complexes were washed four times with RIPA buffer, eluted by boiling at 
95 °C for 5 min and then subjected to western blot analysis to detect V5–PFN1 
and actin. Antibodies: mouse anti-V5 (1:5,000, Invitrogen); mouse anti-β-actin 
(1:1,000, Sigma); and goat anti-mouse 800CW (1:10,000, LICOR). To 
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demonstrate conjugation of mutant PFN1 by ubiquitin, HA–ubiquitin was co-
transfected into N2A with either V5–PFN1(C71G) or V5 vector at a ratio of 1:1. At 
48 h after transfection, cells were lysed and soluble fractions were prepared as 
described above. NP-40-resistant pellets were further dissolved in RIPA buffer 
and immunoprecipitated with 1 µg anti-V5 antibody and washed with lysis buffer 
three times. Western blot analysis was performed with an anti-HA-biotin antibody 
(1:2,000, sigma) and IRDye 800CW streptavidin (1:2,000, LI-COR). After 
stripping the membrane, it was reprobed with mouse anti-V5 antibody (1:5,000, 
Invitrogen). 
Primary motor neuron culture, transfection and immunofluorescence 
Primary motor neurons from embryonic day (E)13.5 mouse embryos were 
isolated, cultured and transfected as previously described (Fallini et al, 2010). 
Ubiquitin protein fused to an HA tag was cloned into the pcDNA plasmid by PCR 
amplification. To inhibit proteasome activity, cells were treated with 10 µM 
MG132 for 12 h. Motor neurons were fixed for 15 min with 4% paraformaldehyde 
in PBS two or three days after transfection, as indicated. Anti-V5 (1:1,000; 
Invitrogen), HA (1:1,000; Cell Signaling Technology), TDP-43 (1:500, 
ProteinTech Group), FUS (1:500, Bethyl labs), SMN (1:500, Santa Cruz) and 
PFN1 (1:500, Sigma) antibodies were incubated overnight at 4 °C. Dylight488-, 
Cy3-, Cy2- or Cy5-conjugated secondary antibodies (Jackson Immunoresearch) 
were incubated for 1 h at room temperature. F-actin and G-actin were labelled 
with rhodamine-conjugated phalloidin (1:1,000, Invitrogen) and Alexa488-DNase 
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I (1:250, Invitrogen), respectively. Z-series (5–10 sections, 0.2 µm thickness) 
were acquired with an epifluorescence microscope (Ti, Nikon) equipped with a 
cooled CCD camera (HQ2, Photometrics). Images were deconvolved 
(Autoquant, MediaCybernetics) and analysed. The growth cone area and the 
fluorescence intensity for F-actin and G-actin staining was measured using 
ImageJ software. The ratio between the two values was averaged and compared 
between different conditions. Statistical significance was assessed using 
Kruskas–Wallis one-way ANOVA test and Dunn’s post-hoc test. For the analysis 
of axon length, cells were fixed and stained to detect V5–PFN1 at 3 days after 
transfection. Low magnification images (×10) were acquired and, if necessary, 
reassembled in Adobe Photoshop. The axon was identified morphologically as 
the longest neurite. The length of the longest axon branch was measured using 
ImageJ plug-in NeuronJ (Meijering et al, 2004). Statistical significance was 
assessed with the Kolmogorov–Smirnov test. 
Immunohistochemistry 
Paraffin-embedded sections from post-mortem human spinal cord (8 µm thick) 
were deparaffinized and endogenous peroxidase activity was blocked with 3% 
hydrogen peroxide at 40 °C. Sections were then incubated with normal horse 
serum for 15 min at 40 °C, followed by anti-PFN1 primary antibody (1:2,000, 
Sigma rabbit polyclonal) or anti-pTDP-43 (1:8,000, Cosmo Bio) diluted in 1% 
BSA overnight at 4 °C. The next day, sections were incubated with biotinylated 
secondary antibody for 30 min at 37 °C followed by avidin–biotin peroxidase 
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complex (Vector Laboratories) for 60 min at 37 °C. DAB (3,3′-diaminobenzidine) 
was used as the chromogen (for colour development); tissues were then 
counterstained with haematoxylin. 
LDH cell viability assay 
HEK293 cells were plated into 96-well plates at a density of 10,000 cells, and 
transfected with PFN1 constructs using Lipofectamine 2000 (Invitrogen). Cells 
with transfection cargo were used as controls. At 24 hours after transfection, cells 
were subject to cell viability analysis using CytoTox-ONE Homogeneous 
Membrane Integrity Assay (Promega) according to manufacturer’s protocol.  
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PREFACE TO CHAPTER III: 
 
Chi-Hong Wu performed and analyzed all the experiments presented in this 
Chapter. 
 
The work presented in this Chapter aimed to characterize ALS-linked PFN1 
mutations in a novel Drosophila model. All data were included and being 
prepared for publication with the exception of Figure 2A-C, Figure 10A, Figure 
12, Figure 13 and Figure 14D.  
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CHAPTER III: FUNCTIONAL DISSECTION OF DROSOPHILA MODELS 
EXPRESSING ALS-LINKED PFN1 MUTAIONS 
3.1 Introduction 
Drosophila melanogaster has been widely used as an in vivo organism to 
model neurodegenerative diseases including ALS (Lanson et al., 2011; Li et al., 
2010; Watson et al., 2008). It presents many advantages over other common 
model organisms. It has relatively shorter lifespan, which allows us to monitor 
adult phenotypes caused by ALS mutations in months. It is also advantageous to 
use GAL4-UAS binary expression system to dissect functions of gene of interest 
in a tissue specific manner (Brand and Perrimon, 1993). Furthermore, Drosophila 
has small and non-redundant genome, and more than 60 percent of fly genes 
have homologs in the human genome (Wangler et al, 2015); therefore it can be 
used to conduct genetic screens in order to elucidate relevant cellular pathways. 
Overexpression of ALS-linked proteins in Drosophila have led to many 
cell-type specific phenotypes such as rough eyes associated with retinal 
degeneration (Hanson et al, 2010; Li et al, 2010; Ritson et al, 2010; Lanson et al, 
2011) and wing defects (Xia et al, 2012; Yang et al, 2015). Importantly, when 
expressed in motor neurons, these proteins reduce lifespan and impair 
locomotion (Watson et al, 2008; Estes et al, 2011), reflecting motor dysfunctions 
observed in ALS patients.  
On a cellular level, neuromuscular junction denervation associated with 
synaptic loss is frequently observed in ALS patients and rodent models (Fischer 
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et al, 2004). Thus it is plausible ALS-linked protein mutants focally impair 
synaptic functions and eventually lead to axon retraction and neurodegeneration.  
Fly larval NMJ is a well-established system for studying synaptic function and 
morphology (Keshishan et al, 1996; Menon et al, 2013). Termini of larval 
segmental nerves form a series of varicosities where they contact and innervate 
the muscles. These “boutons” contain active zones where neurotransmitters are 
released, and have a stereotyped beads-on-a-string pattern, allowing us to 
quantify and compare bouton morphology among different genotypes. At 3rd-intar 
larval stage, ALS-linked proteins have led to abnormal morphologies of 
neuromuscular junctions including altered bouton numbers and sizes (Estes et al, 
2011; Xia et al, 2012) and increased satellite bouton numbers (Estes et al, 2011), 
indicating the importance of ALS-linked proteins in maintaining the integrity of 
NMJs. Notably, overexpression of wild-type ALS-linked proteins can also cause 
these phenotypes in different degrees of severity (Hanson et al, 2010; Li et al, 
2010; Estes et al, 2011; Xia et al, 2012).  
The identification of these phenotypes is invaluable because they can 
serve as readout for forward or reverse genetic screens in order to uncover novel 
cellular pathways altered by ALS-linked proteins. In 2015, Taylor, Gao and 
colleagues introduced a new C9orf72 model and by conducting genetic screens 
using deficiency lines, they discovered that in the presence of expanded G4C2 
repeats, nucleocytoplasmic transport was impaired (Freibaum and Lu et al, 
2015).  Their finding is pivotal in that it sheds light on largely elusive C9orf72 
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pathogenesis. Likewise, Freeman and colleagues first reported that TDP-43 
induced adult-onset NMJ degeneration in fly legs. They further utilized this novel 
adult leg NMJ assay to uncover genetic interactions between TDP-43 and 
several proteins involved in chromatic modeling and RNA export (Sreedharan et 
al, 2015). On the other hand, from a reverse genetic approach, Bonini and 
colleagues confirmed TDP-43 toxicity was modified by phosphorylated eIF2α, a 
component in stress granules (Kim et al, 2014). These important findings not only 
contribute to understanding of ALS pathogenesis, they also emphasize the 
strength of Drosophila as a tool to decode cellular mechanisms that underlie 
neurodegeneration.  
Chickadee is the Drosophila PFN1 ortholog (Cooley et al, 1992), and the 
homology between chickadee and PFN1 is approximately 30 percent (Figure III-
1C). Although the amino acid residues where ALS mutations locate are not 
conserved, previous literature suggests that structural similarity of profilin from 
different species may be more crucial than sequence identity in conserving its 
functions (Witke, 2004). In support of this notion, Gitler and colleagues reported 
that in yeast, human PFN1 functionally rescued PFY mutants despite their low 
sequence conservation (Figley et al, 2014). 
To further characterize how ALS-linked PFN1 mutations lead to 
neurodegeneration in vivo, we generated a novel Drosophila model expressing 
human wild-type and mutant PFN1. We first determined if human PFN1 was 
functionally conserved in the Drosophila system. To investigate if mutant PFN1 
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impair neuromuscular junctions, we expressed PFN1 in motor neurons and 
stained larval NMJs with various synaptic markers. We conducted image analysis 
focusing on structural changes and alteration of F-actin content. To clarify if 
mutant PFN1 cause progressive locomotion defects in adults, we expressed 
PFN1 in motor neuron and measured locomotion at different ages. We also 
monitored their lifespan to determine if PFN1 overexpression affects longevity. 
Finally, to test if mutant PFN1 aggregates in vivo, we performed 
immunohistochemistry and molecular solubility analysis to detect the presence of 
PFN1 aggregates. 
 
 
 
 
 
 
 
 
 
 
 
73 
 
3.2 Results 
Human PFN1 rescues lethality of chickadee knockdown in motor neurons and 
glia. 
To characterize the contribution of PFN1 mutations to neurodegeneration 
in vivo, we generated transgenic Drosophila models expressing human PFN1 
with an N-terminal V5 tag. Because these human PFN1 constructs were 
randomly inserted into the Drosophila genome with P-element, we selected 
clones with similar expression levels among genotypes for further studies 
(Figure III-1A,B). Since human PFN1 and Drosophila chickadee are not 
conserved (Figure III-1C), we first asked whether human PFN1 could functionally 
substitute Drosophila chickadee. In larval NMJs, we first determined chickadee 
was enriched in peripheral glia enwrapping segmental neurons and expressed 
weakly in axons (Figure III-2A-C). Chickadee is an essential gene (Verheyen et 
al, 1994), and its knockdown by RNAi in these tissues led to pupal death (Figure 
III-2D-E). When we expressed human PFN1 under chickadee-deficient 
background, it fully rescued pupal death in both motor neurons and glia. The 
expression of UAS-mCD8GFP in the same RNAi background failed to rescue the 
lethality, indicating that this effect was not due to dilution of UAS lines. This result 
suggested that human PFN1 could functionally replace Drosophila chickadee in 
the central nervous system. Surprisingly, the expression of PFN1 mutants also 
fully rescued pupal death, suggesting that these mutants are functional at early 
developmental stage. 
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Figure III-2.  Human PFN1 rescue pupal death caused by RNAi knockdown 
of chickadee in motor neurons and glia.  
 
(A) Endogenous chickadee is enriched in peripheral glia. UAS-mcherry-NLS was 
driven by Repo-Gal4 and used as a glial nucleus marker. (B,C) Confirmation of 
presence of chickadee in peripheral glia. Chic knowndown by HMS00550 
depleted chickadee in glia. Noted that chickadee is expressed weakly in 
segmental axons. Scale bar = 10 um. (D) Human PFN1 rescue of pupal death 
caused by chickadee knockdown in motor neurons. Genotypes= OK371-
Gal4>UAS-PFN1 WT, UAS-chic RNAi (HMS00550); OK371-Gal4>UAS-PFN1 
C71G, UAS-chic RNAi; OK371-Gal4>UAS-PFN1 M114T, UAS-chic RNAi; 
OK371-Gal4>UAS-mCD8-GFP, UAS-chic RNAi. Rescue efficiency was 
normalized to PFN1 WT. (E) Human PFN1 rescue of pupal death caused by 
chickadee knockdown in glia. Genotypes= repo-Gal4>UAS-PFN1 WT, UAS-chic 
RNAi; repo-Gal4>UAS-PFN1 C71G, UAS-chic RNAi; repo-Gal4>UAS-PFN1 
M114T, UAS-chic RNAi; repo-Gal4>UAS-mCD8-GFP, UAS-chic RNAi. Error bars 
represent S.E.M. throughout the study. n.s. not significant, *P< 0.05, **P< 0.005, 
***P< 0.0005, ****P<0.0001, one-way ANOVA and Tukey post hoc test 
throughout the study unless stated otherwise. chic = chickadee.  
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PFN1 overexpression increases protrusion and ghost bouton formation in larval 
neuromuscular junctions. 
To further investigate if mutant PFN1 have a loss-of-function effect on F-
actin formation at the NMJ, we looked at 3rd instar larval neuromuscular 
junctions (NMJ). We chose NMJs on muscle 4 because they are generally flatter 
and provide a better platform to monitor actin cytoskeleton (Pawson et al, 2008). 
Overexpression of profilin1, either wild type or mutant, did not alter the number 
and size of major boutons (Figure III-3A-C). However, PFN1 overexpression led 
to the formation of filamentous protrusions extending from boutons and less 
frequently, from the axonal shafts (Figure III-3D).  We also observed an increase 
in ghost boutons, which are a type of immature small boutons that lack the 
postsynaptic marker Disc-large (Figure III-3E,F). When comparing wild-type and 
mutant PFN1, we found that M114T PFN1 had significantly fewer protrusions and 
ghost boutons while C71G profilin 1 yielded more variable results (Figure III-
3D,F). Despite these morphological changes, we did not detect any synaptic 
retraction (Figure III-4A-D). Larval crawling assay also showed that 3rd instar 
PFN1-expressing larvae expressing either wild-type or mutant PFN1 
demonstrated normal crawling ability compared to controls (Figure III-4E). Taken 
together, our data suggest that although PFN1 overexpression did not lead to 
locomotion dysfunction or synapse retraction at 3rd instar larval stage, PFN1 
M114T has a partial loss-of-function effect on promoting protrusion formation in 
larval NMJs. 
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Figure III-3. PFN1 overexpression induces formation of protrusions and 
ghost boutons without altering major bouton morphology in larval NMJ. 
 
(A) Visualization of 3rd instar larval NMJs in muscle 4 at segment A3.  PFN1 
overexpression did not alter general synaptic morphology including number and 
size of major boutons but induced formation of protrusions and ghost boutons at 
axon termini. Horseradish peroxidase(HRP) labels axonal membrane. Disc large 
(Dlg) is homolog of PSD-95 and used as a post-synaptic marker. Scale bar = 10 
µm. (B) Quantification of major bouton number (animals analyzed:  Driver only 
=10, WT =10, C71G =13, M114T =14) (C) Quantification of major bouton size 
(animals analyzed:  Driver only =6, WT =9, C71G =13, M114T =8). (D) 
Quantification of protrusion number (animals analyzed:  Driver only =10, WT =10, 
C71G =13, M114T =14) (E) Visualization of ghost boutons in NMJs 
overexpressing PFN1 WT. Ghost bouton (indicated by arrows) was defined as a 
small immature bouton extending from the axonal shaft or major boutons without 
apposition to Dlg. Scale bar = 10 µm. (F) Quantification of ghost bouton number. 
PFN1 M114T induced significantly less protrusion and ghost bouton formation 
than PFN1 WT. (animals analyzed:  Driver only =10, WT =10, C71G =13, M114T 
=14). 
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M114T PFN1 has a loss-of-function effect on F-actin formation in larval NMJ.  
To further investigate whether the formation of these protrusions 
depended on actin polymerization, we utilized flies transgenic for UAS-lifeact-
GFP.  Lifeact is a 17-amino-acid peptide that binds to F-actin and has been used 
widely to monitor F-actin dynamics in vivo (Riedl et al, 2008). Lifeact-GFP 
coexpression with profilin1 confirmed that the protrusions induced by PFN1 
overexpression were rich in F-actin (Figure III-5A-D). We also confirmed that 
PFN1 M114T formed much fewer filopodia than wild type profilin1 (Figure III-5E). 
However, the average length of filopodia was similar among wild type and mutant 
PFN1 (Figure III-5F). We also quantified F-actin levels within the whole synaptic 
regions to measure the effects of mutant PFN1 on overall actin polymerization. In 
the absence of PFN1 overexpression, F-actin formed discrete GFP positive 
patches within boutons and along axonal shafts (Figure III-6A). When PFN1 was 
overexpressed, the number and the average size of F-actin patches drastically 
increased (Figure III-6B-E). We also observed a trend toward a mild reduction in 
the number of F-actin patches when M114T mutant was expressed compared to 
WT overexpression (Figure III-6F), supporting the hypothesis that PFN1 M114T 
has a partial loss-of-function effect on actin polymerization, particularly in the  
presynaptic regions of NMJs.      
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PFN1 overexpression reduces basal number of satellite boutons and depletes 
synaptic vesicles 
Satellite boutons are another type of small boutons that sprout from major 
boutons. Unlike ghost boutons, satellite boutons contain active zones and are 
apposed by postsynaptic markers (Torroja et al, 1999), suggesting a functional 
difference between these two types of boutons. In our experiments, satellite 
boutons were occasionally found in control NMJs fro, animals reared at 29°C 
(Figure III-7A). We found that overexpression of both wild type and mutant PFN1 
reduced basal number of satellite boutons (Figure III-7B). Because alterations in 
the number of satellite boutons have been observed in mutants that affect 
endocytosis and actin cytoskeleton (Marie et al, 2004; Dickman et al, 2006; 
Rodal et al, 2008), we then asked whether PFN1 overexpression would change 
synaptic content. Using cysteine-string-protein (CSP) to label synaptic vesicles, 
we saw a reduction in synaptic vesicles in NMJs of PFN1-overexpressing flies 
(Figure III-7C). By comparison, mutant PFN1 reduced the synaptic vesicles to a 
similar extent to wild type PFN1 (Figure III-7D), implying the mechanisms 
underlying protrusion formation and satellite bouton reduction may be different.  
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Figure III-7. PFN1 overexpression leads to reduction in synaptic vesicles 
and satellite bouton number in larval NMJ. 
 
(A) Representative image of satellite boutons in control NMJs. Arrows indicates 
satellite boutons. Scale bar = 10 µm. (B) Quantification of satellite bouton 
number. PFN1 overexpression reduces number of basal satellite boutons at 
29°C. (animal analyzed: Driver only =10, WT =10, C71G =13, M114T =14) (C) 
NMJs stained with CSP and HRP. Cysteine string protein (CSP) was used as a 
presynaptic marker to label synaptic vesicles. Scale bar = 10 µm. (D) 
Quantification of CSP intensity per synaptic region. Synaptic area was delineated 
by HRP. Profilin 1 overexpression resulted in a reduction in CSP intensity in the
whole synapse. (animal analyzed: Driver only =8, WT =6, C71G =7, M114T =8)  
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PFN1 overexpression leads to adult locomotion defects and reduces lifespan 
We then asked whether PFN1 overexpression would cause locomotion 
defects at adult age, which reflects adult-onset motor dysfunction in ALS. 
Negative geotaxis is a behavior commonly used to measure age-associated 
locomotion decline (Gargano et al, 2005) and the effects of ALS-associated 
genes on adult locomotion in flies (Watson et al, 2008; Estes et al, 2011). We 
thus used OK371-Gal4 to drive expression of PFN1 in glutamatergic neurons, 
which included motor neurons (Mahr et al, 2006), and measured negative 
geotaxis (climbing assay) at different ages. At five days post-eclosion (d.p.e.), 
flies expressing wild-type and M114T PFN1 had climbing ability similar to driver-
only controls, while there was a mild reduction in flies expressing C71G PFN1. At 
10 d.p.e., all PFN1-expressing flies showed significant climbing defects, and by 
day 20, almost none could climb even without external agitation (Figure III-8A). 
These defects were reproduced using multiple clones of PFN1 expressing flies to 
exclude possible position effects (Figure III-8B). Interestingly, we observed a 
trend whereby wild-type PFN1 overexpression led to more severe defects than 
mutant PFN1 from day 10 onwards, although it did not reach statistical 
significance. PFN1 overexpression in motor neurons also drastically reduced 
lifespan and in this analysis, wild-type PFN1 was significantly more severe than 
mutant PFN1 (Figure III-8C). Bosco and colleagues reported that ALS-linked 
mutations destabilize PFN1 in vitro and increase protein turnover in mammalian 
cultured cells (Boopathy et al, 2014). To test if the difference of toxicity was due 
88 
 
to change in expression level secondary to protein degradation, we checked 
PFN1 protein level from flies at 10 d.p.e., when the climbing defects started to 
manifest.  We did not detect reduced protein levels of mutant PFN1 (Figure III-
8D,E), implying that the difference in toxicity did not result from protein 
degradation. Interestingly, Western blot analysis of PFN1 protein level at 10 
d.p.e. showed that PFN1 M114T had higher level than WT and C71G. It has yet 
to be clarified whether this difference is due to the hypothesis that PFN1 WT is 
more toxic, thereby resulting in increased motor neuron death. We then repeated 
climbing assays and lifespan analysis with chickadee-expressing flies and found 
similar defects compared to wild-type human PFN1 (Figure III-9A-C). This 
suggested that the toxicity was not an artificial outcome of overexpression of 
exogenous human PFN1, but more likely caused by dysregulation of cellular 
pathways in which native PFN1 is involved.  To test whether PFN1 
overexpression had a similar impact in different cell types, we expressed PFN1 in 
glia and measured lifespan. Interestingly, as in motor neurons, wild-type PFN1 
overexpression drastically reduced lifespan, while flies expressing mutant PFN1 
had lifespan similar to controls (Figure III-10A). On the contrary, PFN1 
overexpression in the eye tissue including photoreceptor cells (driven by GMR-
Gal4) did not cause any rough eye phenotypes (Figure III-10B). Taken together, 
our data show PFN1 overexpression results in adult progressive locomotion 
defects, on which mutant PFN1 has a partial loss-of-function effect. It also 
indicates the cellular sensitivity to increased PFN1 level is cell-type specific.  
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Figure III-8. PFN1 overexpression in motor neurons leads to adult 
locomotion defects and shorter lifespan. 
 
(A) Climbing assay of adult flies expressing PFN1. PFN1 overexpression in 
motor neurons (driven by OK371-Gal4) led to severe climbing defects from 10 
d.p.e. (B) Confirmation of climbing defects. Overexpression of multiple clones of 
wild-type PFN1 all led to severe toxicity. (C) Lifespan of adult flies expressing 
PFN1. PFN1 overexpression in motor neurons resulted in shorter lifespan 
compared to driver only control. PFN1 WT was significantly more toxic than 
C71G and M114T. Log-rank test: WT vs. control, P < 0.0001; WT vs. C71G, P < 
0.0001; WT vs. M114T, P < 0.0001; C71G vs. control, P < 0.0001; C71G vs. 
M114T, P < 0.0001; M114T vs. control, P < 0.0001. (D) Western blot analysis of 
PFN1 expression in motor neurons at different ages. There was no decrease in 
protein level in C71G and M114T both at 3 and 10 d.p.e. (E) Quantification of 
profilin 1 expression level at 10 d.p.e.  d.p.e = days post-eclosion.  
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PFN1 overexpression results in adult leg NMJ degeneration  
Because PFN1 overexpression in motor neurons resulted in adult 
locomotion defects and shorter lifespan, we wondered if there were signs of axon 
degeneration at adult stage. mCD8-GFP expressed in motor neurons (driven by 
OK371-Gal4) has been reported to outline structures of adult NMJ and label 
active zones (Sreedharan et al, 2015, Figure III-11A). Utilizing this assay, we co-
expressed PFN1 and 2 copies of mCD8-GFP in motor neurons and monitored 
NMJ integrity at 10 d.p.e., when climbing defects manifested. While the NMJ 
remained intact in control flies, PFN1 overexpression resulted in enlargement 
and disorganization of the NMJ, accompanied by loss of GFP puncta (Figure III-
11B). This result , together with the finding in 3rd instar larval stage, supports the 
hypothesis that PFN1 overexpression causes adult-onset neuromuscular 
degeneration. 
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Superoxide dismutase (SOD) genetically interacts with PFN1 in locomotion and 
NMJ morphology 
Given the observed morphological and behavioral phenotypes, we 
decided to investigate possible molecular mechanisms that account for PFN1-
induced toxicity. Thus, we conducted epistatic studies to test if other ALS-
associated genes interact with PFN1 in common cellular pathways.  Interestingly, 
we found that heterozygous amorphic SOD mutant SODn1 enhanced PFN1-
induced climbing defects, while loss-of-function ataxin-2 and TDP-43 mutants 
failed to modify this phenotype (Figure III-12A). SOD1 is a cytoplasmic 
superoxide dismutase responsible for scavenging cellular free superoxide 
radicals (Fridovich, 1986), and it is one of the most common ALS-linked genes 
(reviewed in Renton et al, 2014).  To be noted, SODn1 is a loss-of-function allele 
of Drosophila SOD1 homolog that contains a point mutation that disrupts the 
hydrogen bond on the SOD dimer surface. It also showed that SODn1 mutant 
further reduced lifespan of PFN1-over expressing flies, although the 
heterozygous allele alone also led to a mild reduction in longevity (Figure III-
12B). Western blot analysis of 10-day-old flies demonstrated that SODn1 did not 
alter PFN1 level. (Figure III-12C,D). Heterozygous SODn1 mutant alone did not 
impair climbing, suggesting this enhancement was not additive. (Figure III-12E).  
Importantly, SODn1 mutant failed to enhance climbing phenotypes caused by 
PFN1 C71G and M114T (Figure III-12E). We attempted to confirm this genetic 
interaction using another amorphic SOD mutatnt, SODn64, which affected 
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enzymatic activity of SOD more drastically than SODn1 (Phillips et al, 1995). 
Surprisingly, SODn64 mutant enhanced climbing defects in both wild-type and 
mutant PFN1 (Figure III-12F). This differential modification hinted at a partial 
loss-of-function effect of ALS-linked PFN1 mutations on their genetic interaction 
with SOD. SOD is a cytoplasmic superoxide dismutase involved in free radical 
reduction. To investigate if PFN1-induced phenotypes could also be modified by 
other oxidative stress-associated components, we tested SOD2, a mitochondria-
specific superoxide dismutase. Unlike SOD, loss-of-function SOD2Δ02 mutant did 
not modify PFN1-induced climbing defects (Figure III-12G). We then wondered if 
SODn1 mutant could modify larval NMJ changes caused by PFN1 
overexpression.  Sweeney and colleagues have used homozygous amorphic 
SOD mutants and pharmacological stressors to demonstrate that oxidative stress 
results in NMJ overgrowth (Milton et al, 2011). Our data supported their finding 
that homozygous SODn1 mutant increased bouton numbers (Figure III-13A-D).  
Interestingly, while neither heterozygous SODn1 mutant alone nor PFN1 
overexpression led to NMJ overgrowth, the combination of these two conditions 
significantly increased bouton numbers, indicative of an epistatic relationship 
(Figure III-13E). On the contrary, heterozygous SODn1 mutant did not alter 
PFN1-induced filopodia formation (Figure III-13F).  In all, this result corroboratea 
our finding in the locomotion assay that PFN1 genetically interacts with SOD. 
Importantly, ALS-linked PFN1 mutants may have a partial loss-of-function effect 
on this interaction. 
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Mutant PFN1 do not form visible aggregates in this Drosophila model  
Since mutant PFN1 forms cytoplasmic aggregates when overexpressed in 
mammalian cultured cells (Chapter II), we wondered whether these mutants also 
led to protein aggregation in vivo. To test this, we expressed either wild type or 
mutant PFN1 in motor neurons and stained larval ventral nerve cords for 
presence of aggregates. However, we did not detect visible aggregate formation 
of mutant PFN1 (Figure III-14A,B). We also confirmed this result by performing 
solubility analysis of aged fly tissues, in which both wild type and mutant PFN1 
remained in the detergent-soluble protein fractions (Figure III-14C).  Proteasome 
inhibition has been reported to enhance aggresome formation (shown in Chapter 
II). Therefore, we co-expressed human PFN1 and Prosbeta21, a temperature-
sensitive dominant-negative mutant of proteasome subunits, which created a 
proteasome-defective cellular environment (Smyth et al, 1999). 
Immunohistochemistry analysis failed to detect insoluble aggregates (Figure III-
14D). 
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Figure III-12. Amorphic SOD mutants enhance PFN1- induced toxicity.  
 
(A) Modification of PFN1-induced climbing toxicity by other ALS-associated 
proteins. Amorphic SOD mutant SODn1 enhanced climbing defects of PFN1 
overexpression (driven by OK371-Gal4). (B) Lifespan analysis. SODn1 mutant 
reduced longevity of both driver only and PFN1-overexpressing flies. Log-rank 
test: OK371/+ vs. OK371/+; SODn1/+, P < 0.0001; OK371/+; PFN1 WT/+ vs. 
OK371/+; PFN1/SODn1, P < 0.0001. (C,D) Western blot analysis and 
quantification of PFN1 level co-expressed with SODn1 mutant. SODn1 mutant 
did not alter protein level of PFN1. (E) SODn1 mutant enhanced climbing 
phenotype of wild-type PFN1 overexpression but not C71G and M114T. (F) 
SODn64 mutant enhanced both wild-type and mutant PFN1 toxicity. (G) Loss-of-
function SOD2 mutant did not modify PFN1 toxicity. All climbing assays were 
preformed at 10 d.p.e. SOD = superoxide dismutase, Atx2= ataxin 2, TBPH= 
TAR DNA-binding protein-43 homolog, SOD2 =superoxide dismutase 2.  
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Figure III-14. ALS-linked PFN1 mutants do not form aggregates in 
Drosophila tissues.  
 
(A,B) Immunofluorescence staining of profilin 1 in ventral nerve cords from 3rd 
instar larvae. Either PFN1 WT or PFN1 C71G were driven by OK371-Gal4, 
expressed in motor neurons, and stained with V5 antibody. Both proteins were 
mostly localized in the cytoplasm without forming visible aggregates. UAS-
mcherry-NLS was used to label nuclei of motor neurons. Scar bar = 30 µm. (C) 
Western blot analysis of fly head tissues subject to Triton-X 100 soluble (S) and 
insoluble  (I) fractionation. Fly heads were collected at 24 days post-eclosion. (D) 
Staining of PFN1 in ventral nerve cords from 3rd instar larvae under proteasome-
defective background. UAS-Prosβ21 was co-expressed with PFN1 to inhibit 
proteasome. V5 antibody labeled profilin 1, and both WT and C71G remained 
mostly in the cytoplasm without aggregate formation.  
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3.3 Discussion 
 
The cytoskeleton is crucial in maintaining axonal function and structure, 
and gene mutations of several cytoskeletal components have been reported to 
be associated with ALS, such as PFN1, TUBA4A (Smith et al, 2014), DCTN1 
(Puls et al, 2003), NEFH (Figlewicz et al, 1994; Al-chalabi et al, 1999), and 
PRPH (Gros-Louis et al, 2004). However, it is still not fully understood how 
mutations of these cytoskeletal proteins contribute to neurodegeneration. Here 
we established a novel Drosophila model expressing either wild-type or mutant 
human PFN1 in order to elucidate mechanisms underlying neurodegeneration 
caused by mutant PFN1.  Although human PFN1 and its Drosophila ortholog 
chickadee are lowly conserved, we showed that human PFN1 rescues pupal 
death caused by chickadee knockdown in motor neurons and glia, indicative of 
its conserved functions.  
Profilin is involved in various aspects of neuronal functions including 
axonal outgrowth of motor neurons in Drosophila embryos (Wills et al, 1999; Kim 
et al, 2001). It has been shown to be present both in presynaptic (Faivre-Sarrailh 
et al, 1993) and postsynaptic (Giesemann, et al, 2003) sites. Likewise, it is also 
known that synaptic morphology and functions rely on intact F-actin network, and 
mutations in components of the actin cytoskeleton have been shown to cause 
abnormal larval NMJ morphologies (Zhao et al, 2013, Piccioli et al, 2014). To 
clarify how PFN1 regulates integrity of neuromuscular junctions, we expressed 
wild-type or mutant human PFN1 in motor neurons and measured morphological 
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changes in larval NMJs. Although PFN1 overexpression does not alter size and 
number of major boutons, we found that it leads to the formation of protrusions 
and ghost boutons. Davis and colleagues reported similar protrusion formation 
when hts/adducin, an actin capping protein, was depleted in larval NMJ (Pielage 
et al, 2011). This implies that the protrusion formation is likely a result of F-actin 
upregulation. Enrichment of Lifeact-GFP in these protrusions further confirmed 
they are F-actin rich filopodia. This result supports a previous study showing that 
in mouse embryonic fibroblasts, PFN1 overexpression preferentially induces 
filopodia formation (Rotty et al, 2015). 
Interestingly, the same phenotypes have been reported in wild type NMJs 
when they undergo spaced high potassium stimulation (Ataman et al, 2008). In 
the study, Budnik and colleagues found that activity-induced synaptopods were 
detected in live NMJs but hardly preserved after tissue fixation. However, in our 
case, PFN1-induced protrusions are well detected in post-fixed NMJs. It is 
therefore plausible that PFN1 plays an activity-regulated role in the presynaptic 
region. Importantly, we found PFN1 M114T produces fewer filopodia than wild-
type PFN1. While the number of filopodia is reduced, the average length is 
unchanged, suggesting that M114T may affect the initiation, rather than 
elongation, of unbranched F-actin during filopodia formation. It will thus be 
worthwhile further clarifying which components in actin polymerization are 
affected by mutant PFN1. We aslo observed a mild but non-significant decrease 
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in F-actin patches in whole synaptic regions in PFN1 M114T mutant, supporting 
that mutant PFN1 has partial loss-of-function effects on actin polymerization.  
The F-actin network serves as scaffold for regulating the pools and 
recycling of synaptic vesicles (reviewed in Cingolani and Goda, 2008). For 
instance, WAVE complex regulates F-actin assembly in presynaptic NMJ 
terminals, and mutants of Cyfip, a component of WAVE complex, showed an 
increase in satellite boutons and led to endocytic defects (Zhao et al, 2013). We 
found that PFN1 overexpression reduces basal satellite bouton numbers and 
CSP content in whole synaptic areas. We speculate that PFN1 overexpression 
may either promote synaptic vesicle release or regulate its recycling through 
actin-dependent or –independent pathways. However, unlike filopodia formation, 
mutant PFN1 lead to similar reduction in satellite number and CSP signal 
compared to wild-type PFN1. This implies the pathways through which PFN1 
regulate synaptic vesicles and filopodia formation may not overlap. 
In Davis and colleagues’ study, loss-of-function hts/adducin mutant 
resulted in synaptic retractions in larval NMJs (Pielage et al, 2011). These 
retracting synapses maintained residual HRP and postsynaptic DGluR III staining 
but lost presynaptic active zone marker BRP. In our experiments, PFN1 
overexpression does not cause synaptic retraction or alter larval crawling ability 
despite the morphological changes in larval NMJs. Furthermore, although we 
observed partial loss of function in filopodia formation in M114T PFN1, mutant 
PFN1 are also able to rescue pupal death caused by chickadee knockdown and 
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do not affect larval locomotion.  These results suggest that mutant PFN1 do not 
have a deleterious effect (i.e. life or death) at early developmental stage.  
Nonetheless, in adult flies our data showed that PFN1 overexpression in 
motor neurons leads to progressive climbing defects and reduced lifespan. By 
using an adult leg NMJ assay, we also found that PFN1 overexpression leads to 
the disorganization of NMJs.  We argue that PFN1 overexpression may up-
regulate its cellular functions to the extent that it leads to neural toxicity. 
Considering that ALS is an adult-onset progressive neurodegenerative disease, 
our findings are important in that they demonstrate an age-dependent motor 
dysfunction due to PFN1 overexpression. Because mutant PFN1 is significantly 
less toxic than wild-type PFN1 despite similar expression level, we also 
speculate that PFN1 mutants have a partial loss of function, thereby resulting in 
milder toxicity. We cannot exclude the possibility that there are unknown 
pathways affected by mutant PFN1 through gain-of-function mechanisms, and 
that these phenotypes are masked by toxicities of actin dysregulation. Therefore, 
genetic screening on PFN1 mutants will be needed to explore this possibility.  
On a molecular level, our epistatic study also revealed a genetic 
interaction between PFN1 and SOD, another ALS-linked protein. In this study, 
we tested two different amorphic SOD mutants. SODn1 allele contains a point 
mutation that disrupts the hydrogen bond on the SOD dimer surface, and 
SODn1/SODwt heterozygotes maintain 37% of SODwt/SODwt activity. On the other 
hand, SODn64 allele harbors a point mutation that affects binding of SOD1 to it 
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cofactors Cu and Zn ions. SODn64/SODwt heterozygotes result in 12% of 
SODwt/SODwt activity (Phillips et al, 1995).  These two SOD1 mutants 
consistently exacerbated the climbing defects caused by wild-type PFN1 
overexpression. We further confirmed this genetic interaction by showing that 
heterozygous SODn1 allele and PFN1 overexpression have a concerted effect on 
promoting NMJ overgrowth. Notably, only the more severe form SODn64 allele 
modifies the toxicity of ALS-linked PFN1 mutants. This differential modification 
hints that mutant PFN1 may have a partial loss-of-function effect on the genetic 
interaction with SOD.  It has yet to be clarified whether this partial loss of function 
is actin-dependent (which is in line with our other results) or through other 
unknown actin-independent pathways.  
Contrary to SOD1, loss-of-function SOD2 mutant alleles fail to alter the 
climbing phenotype. This result implies that this interaction is specific to SOD1 
and not shared by other cellular components associated with ROS reduction. 
Nonetheless, the SOD alleles we tested possess dominant negative 
characteristics, while SOD2 mutant is a simply loss-of-function amorph. Thus 
their heterozygotes may increase cellular vulnerability to oxidative stress to 
different levels. Likewise, while heterozygous SODn1 mutant does not lead to 
NMJ overgrowth, which is induced by oxidative stress, it moderately reduced 
longevity of adult flies, suggesting that heterozygous SODn1 mutant may still 
induce oxidative stress in adult flies. Therefore, while it is possible that PFN1 
overexpression somehow regulates the activity of SOD1, it is more likely that 
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SOD1 amorph-dependent induction of oxidative stress modulates the functions of 
PFN1, thereby enhancing its toxicity. Future investigation on the molecular 
mechanisms underlying this genetic interaction will shed light on how PFN1 
regulate functions of adult motor neurons during oxidative stress.   
Lastly, in this Drosophila model, we did not detect visible aggregates in 
motor neurons by cell staining or insoluble mutant PFN1 by solubility analysis. 
Proteasome inhibition by co-expression of a dominant-negative proteasome 
subunit mutant Prosbeta21 also failed to promote aggregate formation. It is not 
known if mutant PFN1 possesses the same protein stability or propensity to 
aggregate in different models (e.g. mammalian cell cultures and Drosophila). It is 
also possible that mutant PFN1 gradually develop aggregates during aging, 
which cannot be detected because of early-onset lethality resulting from PFN1 
overexpression. The contribution of aggregates to pathogenesis of ALS has been 
discussed heatedly over the past decades. While some argue that aggregation 
leads to toxic gain-of-function effects that compromise cellular viability (reviewed 
in Peters et al, 2015), it is increasingly recognized that in many aggregate-
forming neurodegenerative diseases, soluble misfolded proteins are the actual 
toxic species, and aggregate formation serves as a protective mechanism by 
sequestering these toxic proteins (Arrasate, et al, 2004; Tanaka et al, 2004; 
Cowan et al, 2013; Cragnaz et al, 2014). Although it is still inconclusive which 
mechanism plays a major role, absence of aggregates in our Drosophila system 
provides a good platform for us to dissect loss-of-function and gain-of-function 
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mechanisms of soluble ALS-linked mutant PFN1 without being confounded by 
the effects contributed by aggregates.   
Taken together, in this Chapter, our data support the findings in Chapter II 
that ALS-linked PFN1 mutants have a loss-of-function effect on actin 
polymerization, particularly in presynaptic NMJ terminals. We also demonstrate 
that PFN1 overexpression results in progressive locomotion defects, shorter 
lifespan, and neuromuscular degeneration in adult flies. Summary of these 
phenotypes is listed at the end of this chapter (Table III-1). These phenotypes 
not only reflect symptoms in ALS patients, but will also be valuable as readout for 
future genetic screens to better understand PFN1-associated neurodegeneration.  
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3.5 Material and methods 
Fly stocks and transgenic flies 
All flies were maintained on standard fly food (molasses, cornmeal, yeast, and 
agar) at 25°C. To increase expression of transgenes, crosses were set at 25°C 
for two days and then shifted to 29°C afterwards in all experiments unless stated 
otherwise. W1118 strain was used as control flies. To generate UAS-V5-hPFN1 
transgenic flies, cDNA encoding wild-type, C71G and M114T PFN1 were 
amplified from constructs previously reported (Wu et al, 2012). They were then 
cloned into pUAST vector to express profilin 1 protein tagged with an N-terminal 
V5 epitope, under control of UAS sequence in the promoter region. The 
constructs were sent for fly injection (BestGene Inc.) The following stocks were 
obtained from Bloomington Stock Center: OK371-Gal4, repo-Gal4, gmr-Gal4, 
act5c-Gal4, tubulin-Gal4, UAS-mCD8::GFP, UAS-mcherry-NLS, UAS-
Prosbeta21, UAS-lifeact-GFP, SODn1, SODn64, and SOD2Δ02.  RNAi line against 
chickadee (HMS00550) was obtained from TRiP RNAi Screening Center at 
Harvard Medical School. UAS-chicE36.5, which was used in initial control 
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experiments, was kindly provided by Dr. Lynn Cooley. TBPHΔ142/Cyo was kindly 
provided by Dr. Fen-Biao Gao.  
 
Western blot and solubility analysis 
Heads of 10 one-to-three-day-old male flies were collected and homogenized in 
SDS-containing loading buffers, and equal amount were loaded onto 4-20% 
SDS-PAGE (Bio-rad), transferred to nitrocellulose membranes through Turboblot 
(Bio-rad), and blotted with antibodies accordingly. For solubility test, heads of 
male flies were first homogenized in lysis buffer containing 0.1% Triton X100, 
150mM NaCl, and 0.1M Tris, pH 8.0 supplemented with protease inhibitor 
cocktail (Roche), and centrifuged at 13000 rpm for 15 minutes. The supernatants 
were collected as soluble fractions. The pellets were then washed with the same 
lysis buffer at least twice, lysed in 8M urea buffers and centrifuged for another 20 
minutes. The final supernatants were collected as insoluble fractions. Antibodies: 
mouse anti-V5 (1:5000, Novus Biologicals), rabbit anti-V5 (1:5000, Novus 
biological), mouse anti-tubulin (E7, 1:1000, DSHB). 
 
Climbing assay and lifespan 
One to three day-old male flies from corresponding crosses were collected, and 
transferred to fresh food vials with density of 20 flies per vial. Flies were allowed 
to recover from anesthesia for at least 2 days before any behavior analysis, and 
food were changed every 2 days to prevent flies from getting trapped in the food. 
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Climbing assays were conducted in the early evenings on day 5, day 10, day 15, 
and day 20. To induce negative geotaxis, all the flies were gently tapped down to 
the bottom of the vials, and their ability to climb up was recorded using a 
standard video camera. Percentage of flies that climbed above 4 cm lines at 10 
seconds was calculated as climbing index. This measurement point was 
empirically determined using control flies. For lifespan analysis, 1 to 3 days old 
male flies were collected into fresh food vials with density of 10 flies per vial. 
Flies were transferred to fresh food vials every 2 days, and surviving flies were 
counted at the time.  
 
Larval crawling assay 
Larval crawling assay was performed as previously described (Nichols et al, 
2012). In brief, 3rd instar wandering larvae were collected and transferred onto a 
1% agarose plate. The crawling distance within one minute was then measured. 
For each genotype, at least 20 animals from two crosses were tested.  
 
Immunohistochemistry 
Ventral nerve cord (VNC) dissection and staining were performed as previously 
described (Wu and Luo, 2006).  In brief, VNCs of 3rd instar larvae were dissected 
in cold PBS and fixed in 4% PFA for 20 minutes. Fixed samples were blocked 
with blocking solution containing 5% normal goat serum and incubated with 
primary antibodies at 4C overnight.  They were then washed for three times with 
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PBT (0.3% Triton-X 100), incubated with secondary antibodies at room 
temperature for three hours and mounted in Vectashield medium. At lease 3 
animals per genotype were analyzed.  
 
Larval NMJ preparation 
Third instar wandering larvae were dissected in HL3.1 buffer and prepared as 
previously described (Brent et al, 2009a, 2009b). In brief, after dissection, larval 
fillets were fixed in 4% paraformaldehyde for 15 minutes, blocked for 30 minutes 
with PBTN buffer containing 0.3% Triton X100, 5% normal goat serum, and 
200mg/ml BSA, and incubated with primary antibodies at 4C overnight. The fillets 
were then washed for several times, incubated with secondary antibodies at 
room temperature for 1.5 hours, and mounted in Vectashield medium. For lifeact-
GFP analysis, ant-GFP antibody was used to amplify the signals. Antibodies: 
mouse anti-Dlg (1:100, DHSB), mouse anti-CSP (1:100, DHSB), rabbit anti-GFP  
(1:1000, Abcam), Cy3-HRP or Cy5-HRP (1:200, Jackson ImmunoResearch).  
 
Larval NMJ analysis 
NMJs on muscle 4 of segment A3 were chosen for all analyses. HRP were used 
to delineate axons and Dlg were used as a post-synaptic marker. Bead-like 
varicosities that were apposed to Dlg were defined as major boutons.  Ghost 
boutons referred to small immature boutons lacking Dlg apposition. Satellite 
boutons were designated if small boutons growing from major boutons or axonal 
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shafts overlapped with Dlg. For filopodia analysis, thin filaments protruding from 
boutons and axonal shafts were labeled with either HRP or lifeact-GFP and 
counted manually. For F-actin patch analysis, Lifeact-GFP positive patches 
larger than 0.1 um2 were counted using particle analysis on ImageJ. The same 
setting and thresholds were applied to all genotypes during image acquisition 
and analysis. For all images, Z-stack images were acquired under 60X objective 
lens using an epifluorescence microscope (Ti, Nikon) equipped with a cooled 
CCD camera. Images were then deconvolved (Autoquant, MediaCybernetics). 
Maximum projections of processed images were then analyzed using ImageJ 
software.  
 
Adult leg NMJ analysis 
Leg NMJ dissection and analysis were performed as previously described 
(Sreedharan et al, 2015). In short, first legs of male flies at 10 d.p.e were 
dissected and mounted directly in halocarbon oil 27. Images were acquired under 
60X objective lens using a spinning-disc confocal microscope (Nikon D-Eclipse 
C1). Maximum projection of NMJs at mid-femur were used for analysis.  
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Statistics analysis 
One-way ANOVA followed by Tukey post-hoc test was used for all experiments 
except for lifespan analysis. For lifespan, Log-rank test was applied. P <0.05 was 
considered statistically significant.   
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CHAPTER IV: GENERAL DISCUSSION AND FUTURE DIRECTION 
ALS is a progressive neurodegenerative disease that causes both upper 
and lower motor neuron death. Approximately 90 percent of ALS cases are 
sporadic (SALS), and 10 percent are inherited (FALS) (reviewed in Renton et al, 
2014). Through genetic studies over the past decades, many gene mutations 
have been identified as causative or associated with FALS, which account for 
about 60% of cases. Nonetheless, it remains unresolved what genetic factors 
contribute to the remaining cases. Adding hues of complexity to the picture, 
these identified genes are involved in various cellular pathways and many gain-
of-function and loss-of-function mechanisms have been proposed for ALS-linked 
gene mutations (reviewed in Robberecht and Philips, 2013). Although these 
efforts contribute to our understanding of ALS pathogenesis, they highlight the 
molecular heterogeneity that underlies this disease.  
Among these identified cellular pathways is the cytoskeletal network. 
Cytoskeleton consists of two major networks, microtubule and actin, each of 
which consists of numerous associated proteins that fine-tune their functions. 
They provide major support for neuronal structures, but also maintain crucial 
functions such as axonal transport and synaptic transmission (Cingolani and 
Goda, 2008). They are particularly important in the case of ALS in that axons of 
motor neurons travel long distance from the spinal cord to distal neuromuscular 
junctions, making them highly susceptible to disruption of cytoskeletal functions. 
ALS-associated gene mutations of several cytoskeletal components have also 
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been reported, such as PFN1, TUBA4A (Smith and Fallini et al, 2014), DCTN1 
(Puls et al, 2003), and NEFH (Figlewicz et al, 1994; Al-chalabi et al, 1999). 
Studies on these mutations have shed light on how cytoskeletal disruption can 
contribute to neurodegeneration.  For instance, Landers and colleagues reported 
ALS-linked mutations in the TUBA4A gene, one of the major subunits of 
microtubules, and these mutants alter incorporation of TUBA4A into microtubules 
and disrupt microtubule dynamics through a dominant-negative mechanism 
(Smith and Fallini et al, 2014). These findings thus lend strong support to the 
relevance of cytoskeletal alteration to ALS pathogenesis.  
Using exome sequencing, our genetic study identified several mutations in 
the PFN1 gene, C71G, M114T, E117G and G118V. Profilin 1 is a mostly 
cytoplasmic protein of about 15 kDa (reviewed in Witke, 2004). It has high affinity 
to G-actin, and promotes actin polymerization under optimal concentration. Apart 
from actin, in vitro studies demonstrate that profilin 1 also interacts with 
phospholipids (PI(4,5)P2) and ligands containing PLP stretches, indicating it 
engages in various signaling pathways. Nonetheless, it is still unknown whether 
ALS-linked PFN1 mutations disrupt these functions or even pose gain-of-function 
mechanisms that lead to neurodegeneration.  
Towards this end, in this dissertation we have characterized ALS-linked 
PFN1 mutations in both mammalian cultured cells and Drosophila models. In 
cultured cells, we first demonstrate that ALS-linked PFN1 mutants form 
ubiquitinated aggregates. This finding is important in that it recaptures common 
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histopathological hallmarks for ALS (Kanning et al, 2010). We also show that 
ALS-linked PFN1 mutations reduce affinity to actin and alter F-actin/G-actin ratio 
in growth cones of motor neurons, indicating a loss-of-function mechanism.  
These mutants also have a deleterious impact on neuronal morphology (Chapter 
II). In order to better understand how ALS-linked PFN1 mutants lead to 
neurodegeneration in vivo, we generate a novel Drosophila model expressing 
human PFN1 (Chapter III). In larval NMJs, ALS-linked PFN1 mutants have a 
partial loss-of-function effect on filopodia formation. In adult flies, overexpression 
of wild-type PFN1 alone causes locomotion defects, shorter lifespan and NMJ 
disorganization. These defects indicate that PFN1 level influences function of 
adult motor neurons. Interestingly, ALS-linked PFN1 mutants result in milder 
toxicity compared to wild-type PFN1. This difference further supports ALS-linked 
PFN1 mutants possess partial loss-of-function effects in regulating its cognate 
cellular pathways. Taken together, our work has contributed to understanding of 
PFN1-associated ALS pathogenesis. Because PFN1 overexpression results in 
locomotion defects and adult NMJ disorganization, our Drosophila model will also 
serve as a valuable tool to dissect molecular mechanisms of PFN1-induced 
neurodegeneration.  
 
4.1 Propensity to aggregate of ALS-linked PFN1 mutants 
In Chapter II, we demonstrate ALS-linked profilin 1 mutants possess the 
propensity to aggregate by showing they form ubiquitinated aggregates in 
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primary motor neurons and immortalized cell lines. Molecular analyses also 
confirm these mutants are re-localized in detergent- resistant fractions and 
conjugated with poly-ubiquitin.  Proteasome inhibition by MG-132 further 
enhances aggresome formation, indicating ubiquitin-proteasome system is major 
machinery for clearance of misfolded ALS-linked mutant proteins (Tyedmers et 
al, 2010). We also attempt to confirm whether we can detect aggregates in 
tissues from ALS patients harboring PFN1 mutations. Surprisingly, western blot 
analysis shows there is no increased insoluble PFN1 fraction in patient-derived 
lymphoblast cell lines harboring C71G mutation. We speculate that cellular 
environments may be different in immune and central nervous system, thereby 
rendering different cellular susceptibility to aggregation. Future studies on neural 
tissues or motor neurons derived from iPSCs of ALS patients will help to confirm 
this speculation. 
It is also interesting that different ALS-linked PFN1 mutations have varied 
propensity to aggregate. In Chapter II, using cellular staining and solubility 
analysis, we demonstrate that C71G mutation confers the highest propensity to 
aggregate. This result is also supported by a later study showing recombinant 
profilin 1 C71G mutant misfolds most drastically under in vitro denaturing 
condition (Boopathy et al, 2014). In comparison, another mutation E117G, which 
was observed in non-ALS controls and SALS patients in our genetic study, does 
not form aggregates in cultured cells and remains soluble in solubility analysis. 
Because this mutant also maintains similar affinity to actin compared to wild-type 
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profilin 1, we argue that this mutation may be non-pathogenic or pathogenic but 
less penetrant. Our data suggest the latter because when the proteasome is 
inhibited, profilin 1 E117G starts forming aggregates while wild-type profilin 1 
remains mostly diffuse. In support of this finding, another genetic study reports 
that E117G is a moderate risk factor for FALS (Fratta et al, 2014), indicative of its 
inherent pathogenicity.    
The presence of profilin 1 aggregates also raises the possibility that they 
may pose a gain-of-function mechanism by sequestering other cellular factors. 
Indeed, in primary motor neurons transfected with mutant profilin 1, we find that 
approximately 30% of profilin 1 aggregates co-stain TDP-43, another ALS-linked 
protein. This finding is important for two reasons. Firstly, TDP-43 can often be 
detected in aggregates in ALS patients harboring different gene mutations 
(Neumann et al, 2006). The presence of TDP-43 in mutant profilin 1 aggregates 
further supports that ALS-linked PFN1 mutations recapture common ALS-
relevant histopathological characteristics. Secondly, TDP-43 is an RNA-binding 
protein that localizes mostly in the nucleus and regulates various aspects of RNA 
processing. Thus, translocalization of TDP-43 into the cytoplasm may affect its 
nuclear functions and result in dys-regulated RNA processing and gene 
expression. This sequestration is specific to TDP-43, because we do not detect 
other nuclear proteins, such as SMN and FUS, in PFN1 aggregates. It remains 
unknown whether profilin 1 aggregates also sequester cellular factors other than 
TDP-43, thereby altering different cellular pathways.  
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In Chapter III, we attempt to test if ALS-linked profilin 1 mutants also form 
aggregates in the Drosophila model. In larval ventral nerve cord, where motor 
neurons reside, both wild-type and C71G profilin 1 remain diffuse in the 
cytoplasm without formation of visible aggregates. Because in Chapter II, we 
demonstrate that proteasome inhibition enhances profilin 1 aggregation in 
mammalian cultured cells, we wonder if it also promotes aggregate formation in 
fly tissues. Prosbeta21 is a temperature-sensitive dominant-negative mutant of 
proteasome subunit, which would create a proteasome-defective cellular 
environment (Smyth and Belote 1999). Nonetheless, co-expression of 
Prosbeta21 and profilin 1 C71G in motor neurons does not promote aggregate 
formation, as demonstrated in larval ventral nerve cord. Mild disorganization of 
cellular morphology is found, although it is more likely due to the effect of 
proteasome inhibition. There are several possible explanations for the 
discrepancy between results from mammalian cultured cells and Drosophila 
models.  Firstly, it is not known if mutant profilin 1 possess the same protein 
stability or propensity to aggregate in Drosophila, which may have different 
cellular factors involved in protein folding and thus have different thresholds for 
protein aggregation. Secondly, it is also possible that mutant profilin 1 gradually 
develop aggregates during aging, which cannot be detected because of early 
lethal toxicity resulting from profilin 1 overexpression. Lastly, formation of 
aggregates may require a second-hit triggering factor, such as oxidative stress 
and axonal injury. That said, despite the absence of aggregates in our Drosophila 
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system, this model provides a good platform for us to dissect loss-of-function and 
gain-of-function effects of soluble mutant profilin 1 without being confounded by 
effects contributed by aggregates, as discussed in Chapter III.  
4.2 Loss of function of ALS-linked PFN1 mutations in actin polymerization 
Structural studies of profilin 1 have shown that ALS-linked residues are 
located in close proximity to actin-binding residues (Schutt et al, 1993), raising 
the possibility that ALS-linked PFN1 mutations can impair its actin binding, 
thereby altering actin polymerization. To address this question, we utilized both in 
vitro mammalian cell cultures and in vivo Drosophila models. As demonstrated in 
Chapter II, when transiently transfected in mouse primary motor neurons, ALS-
linked PFN1 mutations reduce F-actin/G-actin ratio in growth cones compared to 
wild-type profilin 1. This result indicates F-actin formation is less efficient in 
axonal termini in the presence of ALS-linked profilin 1. Co-immunoprecipitation 
experiments support this finding by showing that ALS-linked profilin1 mutants 
reduce affinity to actin under stringent buffer condition. In Drosophila, profilin is 
crucial for motor axon outgrowth in the Drosophila embryo because depletion of 
profilin leads to growth cone arrest (Wills et al, 1999). As shown in Chapter III, 
overexpression of either wild-type or mutant profilin 1 in motor neurons does not 
alter synapse formation at early developmental stages, as demonstrated by 
normal bouton number and size in larval NMJs. Nonetheless, it results in 
filopodia formation and increase in F-actin patches in the synapse. This result 
supports a recent study in which profilin 1 overexpression favors formation of 
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filopodia over lamellopodia through promoting linear Ena/VASP-dependent actin 
assembly (Rotty et al, 2015).  This study also stresses the importance of profilin 
1 level in balancing F-actin substructures through coordinating with different 
actin-interacting components. Interestingly, filopodia formation is also observed 
in wild-type larval NMJs when they undergo spaced high-potassium stimulation. 
This filopodia formation is accompanied by up-regulated trans-synaptic Wnt/Wg 
signaling pathway (Ataman et al, 2008). Thus it will be worthwhile investigating 
whether profilin 1 regulates (or is regulated by) activity-dependent synaptic 
function through these pathways. When comparing with wild-type profilin 1, we 
find M114T mutant forms fewer filopodia, and leads to mild reduction in F-actin 
content in the synapse. This result is important in that it corroborates our finding 
in mammalian neuronal cultures that ALS-linked profilin 1 mutants have partial 
loss-of-function effects on actin polymerization, particularly in presynaptic 
regions. Although the number of filopodia is reduced, their average length is 
unaltered by M114T mutant. This raises the possibility that profilin 1 M114T may 
affect initiation, rather than elongation, of unbranched F-actin filaments. Future 
experiments on which actin-interacting components are affected by mutant 
profilin 1 will help to decipher this loss-of-function mechanism. On the other 
hand, while profilin 1 C71G mutant affects actin polymerization in vitro, in 
Drosophila larval NMJs, this mutant leads to a more variable result in filopodia 
formation, difference of which is insignificant compared to wild-type profilin 1. 
One possible explanation is that considering low conservation of sequences 
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between profilin 1 and chickadee, profilin 1 C71G may not reduce its affinity to 
actin or other actin-associated cellular components in Drosophila system as 
much as in mammalian cells. Comparison of structures of profilin 1 C71G and 
chickadee and investigation of their interaction profiles will thus help to confirm 
this speculation. The other possibility is that in mammalian cells, profilin 1 C71G 
possesses highest propensity to aggregate, and therefore may affect actin 
polymerization through sequestering functional actin-associated proteins into 
aggregates. Because we do not detect visible mutant profilin 1 aggregates in this 
Drosophila model (discussed below), we cannot confirm this gain-of-function 
mechanism in vivo.  
In this dissertation, we focus on effects of ALS-linked profilin 1 mutants on 
axonal termini, including growth cones in mammalian motor neurons and 
presynaptic NMJs in flies. Nonetheless, F-actin network also serves as important 
scaffold in postsynaptic regions (reviewed in Cingolani and Goda, 2008). Apart 
from structural support, actin dynamics contributes to anchoring and trafficking of 
neurotransmitter receptors, such as AMPA and NMDA receptors. Profilin has 
been shown to associate with this postsynaptic scaffolding network (Giesemann 
et al, 2003). For instance, profilin interacts with gephyrin, a major component of 
postsynaptic densities (PSDs) in inhibitory synapses. Gephyrin competes with G-
actin and phospholipids for binding to profilin (Giesemann et al, 2003), implying 
the regulatory role of profilin in postsynaptic actin dynamics. Likewise, profilin is 
shown to target to dendritic spines upon electrical and chemical stimulation, and 
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blockage of this targeting alters structure of dendritic spines (Ackermann and 
Matus, 2003). It is thus worthwhile investigating if ALS-linked profilin 1 mutants 
also have loss-of-function effects on post-synaptic F-actin network and result in 
functional consequences. A recent study supports the importance of this direction 
by demonstrating that profilin 1 C71G leads to postsynaptic morphological 
changes including increased dendritic arborization and spine formation in 
hippocampal neurons (Brettle et al, 2015). While the underlying molecular 
mechanisms have yet to be invesitigated, it stresses the potential impacts of 
ALS-linked profilin 1 mutants on both presynaptic and postsynaptic sites of 
neurons.   
4.3 Gain of function of ALS-linked PFN1 mutations in  neuronal integrity 
In section 4.2, we have discussed loss of function of ALS-linked PFN1 
mutations in actin polymerization. Nontheless, since these mutants have high 
propensity to aggregate, it is also likely that the observation of altered actin 
dynamics and neuronal morphology in mouse primary motor neurons is in part, if 
not all, due to gain of function of these profilin 1 mutants. In Chapter II, our 
coimmunoprecipitation result suggests that ALS-linked PFN1 mutations reduce 
its affinity to actin; however, this interaction was measured indirectly using the 
whole cellular lysates. Therefore, it cannot be excluded that this alteration may 
result from toxic effects of profilin 1 aggregates, rather than reduction in actin 
binding. Future experiments utilizing recombinant mutant profilin 1 and actin are 
required to clarify whether their direct interaction is inherently affected. Profilin 1 
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aggregates may impair actin polymerization through several mechanisms. Firstly, 
the formation of profilin 1 aggregates may reduce free profilin 1 available for actin 
binding and thus actin polymerization. Secondly, profilin 1 aggregates may 
sequester other celluar components involved in actin polymerization, thereby 
altering actin dynamics in the growth cones of primary motor neruons. This 
alteration further impairs neuronal morphologies including axonal length and 
growth cone area. Likewise, the presence of profilin  aggregates can also cause 
abnormal neuronal phenotypes through other actin-independent pathways, such 
as sequestering other cellular factors important in neuronal integrity and 
disrupting protein quality control. Thus it will be worthwhile invesitating the 
contributions of these hypotheses to altered neuronal morophologies. On the 
other hand, in Chapter III, studies on larval NMJs suggest that mutant profilin 1 
have less filopodia formation despite the lack of aggregates . This result hints 
that ALS-linked PFN1 mutations can still affect actin polymerization independent 
of aggregate formation. Therefore, it is likely that both gain of function and loss of 
function of ALS-linked PFN1 mutations play a role in neurodegeneration. 
 
4.4 PFN 1 level regulates adult locomotion and lifespan 
The disease onset of ALS is around 50 years of age, accompanied by 
rapid loss of motor functions (reviewed in Wijesekera and Leigh, 2009). To test if 
ALS-linked profilin 1 mutants cause adult-onset locomotion defects, we 
measured climbing ability and lifespan in adult profilin 1-overexpressing flies at 
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different ages. Interestingly, profilin overexpression in glutamatergic neurons, 
which include motor neurons, results in progressive climbing defects and shorter 
lifespan. The behavioral defects are accompanied by signs of neuromuscular 
degeneration in adult legs. These phenotypes are important in that they reflect 
ALS-associated pathogenesis in several aspects. Firstly, profilin 1-induced 
toxicity is specific to ALS-relevant cell types. While profilin 1 overexpression in 
glia results in similarly shorter lifespan, its overexpression in the eye tissue, 
which include photoreceptor cells, does not cause rough eye phenotypes. 
Secondly, profilin 1-induced locomotion defects manifests only in aging flies. At 
3rd instar larval stage, despite morphological changes discussed above, profilin 1 
overexpression does not impair larval crawling ability.  Likewise, at adult stage, 
the locomotion defect is not observed in young flies and shows progressive 
pattern with age. Collectively, our data indicate the importance of profilin 1 level 
in maintenance of locomotion function and integrity of neuromuscular junctions in 
adult flies. It will thus be interesting to see if profilin 1 expression level is altered 
in tissues from ALS patients harboring different gene mutations. Intriguingly, 
when comparing the toxicity caused by wild-type and mutant profilin 1, we find 
that toxicity of wild-type profilin 1 is significantly more severe than ALS-linked 
profilin 1 mutants, particularly in lifespan analysis. This difference does not seem 
due to increased protein turnover of mutant profilin 1, because western blot 
analysis shows no reduced expression level. Therefore we argue that mutant 
profilin 1 have partial loss-of-function effects in up-regulating their cognate 
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cellular pathways to the same toxic level as wild-type profilin 1. It has yet to be 
clarified as to what molecular mechanisms, actin-dependent or –independent, 
underlie this differential toxicity.  
 
4.5 Non-cell autonomous role of PFN1 in neuronal integrity 
Astrocytes are one of the integral components of tripartite synapses that 
contribute to maintenance of synaptic structure and functions (reviewed in Eroglu 
and Barres, 2010). Apart from axons, profilin 1 has been shown to modulate 
astrocytic processes in an actin-dependent manner (Molotkov et al, 2013; 
Schweinhuber et al, 2015). Peripherally, another study demonstrates that proflin 
1 serves as an effector of Rho/ROCK signaling pathway and promotes 
myelination of Schwann cells (Montani et al, 2014). These studies highlight that 
profilin 1 is a multi-functional player in different glia subtypes.  In Chapter III, at 
3rd instar larval stage, we first demonstrate that endogenous chickadee is 
enriched in peripheral glia that enwrap segmental nerves. But in order to clarify 
the contribution of glial profilin 1 to neuronal integrity, it will require further 
confirmation as to whether glial profilin 1 depletion causes wrapping defects and 
affects axonal functions. Likewise, at adult stage, our observation that profilin 1 
overexpression in glia results in toxicity further confirms the importance of profilin 
1 level in different ALS-relevant cell types. Over the last few years, non-cell 
autonomous toxicity has been brought into the picture of ALS pathogenesis 
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(reviewed in llieva et al, 2009 and Valori et al, 2014). For instance, in both ALS 
patients (Rothstein et al, 1995) and ALS rodent models (Howland et al, 2002), 
loss of glial glutamate transporters has been reported, which may cause 
excitotoxicity through disruption of glutamate buffering by glia. By investigating if 
neuronal activity or synaptic transmission is altered with increased profilin 1 level 
in glia, it will elucidate non-cell-autonomous contribution of profilin 1 to 
neurodegeneration. Lastly, similar to motor neurons, wild-type profilin 1 
overexpression in glia results in significantly shorter lifespan than mutant profilin 
1. This result again suggest ALS-linked profilin 1 mutants may have a loss-of-
function effect in glia as well as in motor neurons.  
 
4.6 Advantages of Drosophila models expressing human PFN1 
Throughout this dissertation, we have compared several differences 
between mammalian cultured cells and Drosophila models expressing ALS-
linked PFN1 mutants (summarized in Table IV-1). Despite the lack of 
aggregates, our Drosophila models provide a good platform for following 
applications:  
Identification of genetic interaction between SOD1 and PFN1 
In Chapter III, we discussed the advantage of ALS Drosophila models as a 
genetic tool to identify relevant cellular pathways. In our Drosophila model, 
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profilin 1 overexpression in motor neurons leads to adult phenotypes including 
locomotion defects, shorter lifespan, and leg NMJ degeneration. These 
phenotypes not only stress the importance of profilin 1 level in adult NMJs, but 
can also be used to dissect motor neuron-specific cellular pathways associated 
with profilin 1. Towards this end, we first wonder if profilin 1 and other ALS-linked 
proteins are involved in common cellular pathways. We observe that amorphic 
SOD1 mutants, but not TDP-43 and ataxin-2, modify profilin 1-induced 
locomotion defects, indicative of their genetic interaction. SOD1 is a cytoplasmic 
superoxide dismutase responsible for scavenging cellular free superoxide 
radicals (Fridovich, 1986). We also test SOD2, a mitochondria-specific isozyme, 
to clarify if this modifying effect is shared by other factors involved in reduction of 
oxidative stress. Loss-of-function SOD2 mutants fail to enhance profilin 1-
induced climbing defects, implying the genetic interaction is specific to SOD1. 
We further confirm this genetic interaction by measuring NMJ morphology at 3rd 
instar larval stage. Sweeney and colleagues have used chemical stressors and 
homozygous amorphic SOD mutants to demonstrate that oxidative stress 
induces larval NMJ overgrowth (Milton et al, 2011). In line with their finding, we 
show that homozygous SODn1 mutant results in an increase in bouton number. 
Interestingly, while neither heterozygous SODn1 allele nor profilin 1 
overexpression alone alters bouton number, these two genetic conditions concert 
to induce NMJ overgrowth. Because NMJ overgrowth has been associated with 
oxidative stress, it will be worthwhile to investigate if profilin 1 overexpression 
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contributes to formation of oxidative stress in heterozygous SODn1 background, 
thereby resulting in increased bouton numbers. It is plausible that profilin 1 level 
regulates SOD1 activity, dimerization, or maturation through an unknown 
pathway. Likewise, although SOD1 localizes in the cytoplasm, it is also reported 
to be present in the intermembrane space of mitochondria with elusive roles. 
While some reported that SOD1 in the mitochondrial intermembrane space 
increased toxic ROS (Goldsteins et al, 2008), others showed that targeting of 
SOD1 into the same space rescued axonopathy in Sod1-/- mouse models 
(Fischer et al, 2011). Furthermore, quality control of mitochondria involves their 
fission and fusion, which are particularly important during cellular stress 
(reviewed in Youle and van der Bliek, 2012), and these processes are regulated 
by cytoskeletal dynamics (reviewed in van der Bliek et al, 2013). It is thus 
possible that profilin 1 overexpression can alter actin network that maintains 
mitochondria dynamics, thus affecting the distribution of intermembrane SOD1.  
On the other hand, considering that heterozygous SODn1 mutant 
moderately affects longevity of adult flies, it may still induce oxidative stress, 
despite to a milder level than the homozygous background.  Therefore, it is more 
likely that it is the formation of oxidative stress that modulates functions of profilin 
1, thereby enhancing its toxicity. it will thus be helpful to test if small moleculte-
induced oxidative stress can also modify phenotypes of profilin 1 overexpression. 
It is interesting that in larval NMJ, SODn1 allele does not alter profilin 1-induced 
filopodia formation but contributes to overall NMJ overgrowth. This differential 
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modification hints that in response to oxidative stress, profilin 1 may regulate 
specific F-acitn substructures in presynaptic sites of NMJs. It will be worthwhile 
investigating the functional outcome of this synaptic alteration, e.g. whether 
synaptic transmission is affected. In fact, the relevance of profilin 1 level to 
cellular stress is supported by a study showing that in Drosophila S2 cells, 
osmotic stress upregulates gene expression of chickadee through MAPK/JNK 
pathway (Suganuma et al, 2010). While it still remains unknown as to the 
functional link between profilin and cellular stress, our finding does identify a 
possible role of profilin 1 in regulation of motor neuron function during oxidative 
stress.  
 
To identify novel cellular pathways regulated by wild-type PFN1  
As discussed in Chapter I, profilin 1 interacts with different cellular factors, 
which include G-actin, PLP ligands, and PI(4,5)P2, and is involved in various 
cellular pathways. Profilin 1 has also been implicated in multiple neuronal 
functions, in particular during early development (reviewed in Birbach, 2008). 
However, how it contributes to integrity of adult motor neurons and 
neuromuscular junctions still remains elusive. In the earlier section, we have 
discussed the advantage of this Drosophila model by demonstrating the genetic 
interaction between SOD1 and profilin 1. In order to uncover other novel profilin 
1-associated cellular pathways, the adult NMJ phenotype of profilin 1 
overexpression will serve as valuable readout for genetic screens. Considering 
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ALS is an adult-onset motor neuron disease, this phenotype is age- and cell 
type- relevant. Identification of molecular mechanisms that maintain adult NMJs 
will help us better understand functional roles of profilin 1 in aging motor neurons 
and how its dysregulation may associate with neurodegeneration.  
 
To uncover loss-of-function or gain-of-function mechanisms of mutant PFN1  
Throughout this dissertation, we have demonstrated that ALS-linked PFN1 
mutations lead to partial loss of function in actin polymerization. In particular, in 
our Drosophila model, this observation is mostly inferred from the difference in 
toxicity compared to wild-type profilin 1. Since profilin 1 overexpression alone can 
dys-regulate actin cytoskeleton and cause strong locomotion defects, this toxicity 
may mask any adverse effects that are specific to ALS-linked profilin 1 mutants. 
Thus, it is possible that these mutations have loss-of-function effects in other 
actin-independent pathways or even acquire gain-of-function mechanisms that 
contribute to neurodegeneration. Future genetic screens on NMJ phenotypes in 
flies expressing ALS-linked profilin 1 mutants will thus reveal cellular pathways 
that are altered by mutant prfoilin 1 and shed light on profilin 1-associated ALS 
pathogenesis.  
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